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Background: Depression is two to three times more likely in patients with heart failure 
(HF) than in the general population. Comorbid HF and depression are associated with poor 
outcomes and increased healthcare burden. Clinical guidelines from professional organizations 
recommend routine depression screening in patients with HF. However, screening is not 
systematically implemented in outpatient cardiology settings.  
Objective: The objective of this process improvement project was to create a sustainable 
process for an outpatient cardiology clinic to screen adults with chronic HF for depression, to 
identify patients who have an elevated depression screening score, and to initiate an evidence-
based treatment algorithm for patients evaluated as having elevated screening scores due to 
depression.  
Methods: A nurse practitioner-led process improvement project, set in an outpatient 
cardiology clinic, administered the Patient Health Questionnaire (PHQ-9) tool to patients who 
presented to the clinic for HF care. The score was reviewed by the provider and, if elevated, 
addressed with assessment and plan. Compliance was measured by the percentage of patients 
screened. Clinical impact was measured by percentage of patients with an elevated PHQ-9 score 




Results: Post-implementation results for four Plan-Do-Study-Act cycles were 38%, 68%, 
72%, and 66%, for an overall of 61.9% of patients screened during the project. Twenty-one 
unique patients (13.17%) had elevated PHQ-9 scores; all of whom had a documented assessment 
and treatment plan.  
Conclusions: We demonstrated how a screening protocol and an accompanying 
treatment algorithm can be successfully implemented in an outpatient cardiology clinic. 
Elements of success included a standardized screening protocol, a clinical support algorithm for 
treatment/referral, an optimized electronic medical record that supported the screening tool used, 
and a follow-up system for patients with significant depressive symptoms. Stakeholder 
engagement throughout the project informed iterative changes and provided direction for 
sustainability.   
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CHAPTER 1: THE PROBLEM 
General Problem 
Patients who suffer from heart failure (HF) have increased prevalence of depression 
compared to the general population (Bhatt et al, 2016). Depressed mood and, most profoundly, 
major depression after a HF diagnosis increases the risk of cardiovascular and all-cause mortality 
(Fan et al., 2014). Furthermore, depression and depressive symptoms are predictors of poor 
quality of life (QOL), rehospitalization, and increased healthcare utilization in patients with HF 
(Freedland et al., 2016; Jha et al., 20).  
Local Problem 
To improve patient outcomes including QOL, an opportunity existed to routinely screen 
for and address depression in patients with HF, especially in the outpatient cardiology setting 
where patients are already scheduled for routine follow-up. Personal communication with 
advanced practice registered nurse (APRN) nurse practitioners (NPs) at an outpatient cardiology 
clinic revealed that the many of their patients with chronic HF display symptoms of depression. 
However, patients at this clinic were not routinely screened for depression and depressive 
symptoms were not typically addressed by the provider. On average, patients are seen for follow-
up every one-to-three months by a provider at this HF clinic. For many patients, this means they 
are being seen more frequently by the cardiology clinic providers than by their primary care 
provider. Cardiology specialists engaged in routine depression screening can benefit patients and 




Purpose of the Project 
The project desired outcomes were to create a sustainable process for the cardiology 
clinic to screen patients with chronic HF for depression, to identify patients who have an 
elevated depression screening score, and for providers to initiate an evidence-based treatment 
algorithm for those patients. When screening in a population is implemented, it is important to 
address patients who screen positive and have a pathway to appropriately manage results. 
Providers should review and confirm symptoms of depression, using Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM-V) criteria, and initiate treatment or referral for 
specialized treatment (Celano et al., 2018). Compliance is measured by the percentage which 
screening assessments are completed. The impact of screening (clinical outcome) is measured by 
the percentage of which providers document an assessment and plan for patients who had an 
elevated depression screening score and the percentage of patients for which the provider 
initiated or referred for depression treatment using an algorithm. Providers at this cardiology 
clinic include NPs, physicians, physician assistants, clinical psychologists, pharmacists, and 
licensed clinical social workers (LCSW).  
Clinical Practice Question 
The clinical practice question identified prior to starting this project was: For adults with 
chronic HF, what is the effect of implementing routine screening by an APRN for depression on 
the number of patients identified and referred for depression treatment?  
Significance of Outcomes to Nursing 
Overlap of Depression and HF 
One challenge of comorbid depression in patients with HF is that both conditions have 
symptoms in common, which may ultimately make it challenging for the provider to discern 




intolerance (Kop, Synowski, & Gottlieb, 2011). Symptoms of depression include depressed 
mood, anhedonia, irritability, changes in psychomotor function, feelings of worthlessness or 
guilt, recurrent thoughts of death, and social withdrawal (Kop, Synowski, & Gottlieb, 2011). 
Symptoms of both diseases include fatigue, lack of energy, reduced physical activity, changes in 
weight, changes in sleep, and decreased concentration or cognition (Kop, Synowski, & Gottlieb, 
2011).  
Moreover, while depression and HF share similar symptoms, they also have 
commonalities at the biologic pathways causing bidirectional effects including autonomic 
nervous system dysregulation, neurohormone release, vascular endothelial dysfunction, 
hypercoagulability, and increased inflammatory substances (Aloisi et al., 2019; Celano et al., 
2018; Ishak et al., 2020; Sbolli, Fiuzat, Cani & O’Connor, 2020). Autonomic nervous system 
dysregulation involves increased sympathetic nervous system activity that releases epinephrine 
and norepinephrine neurohormones and reduces feedback control of the hypothalamic-pituitary-
axis, thus, causing increased levels of cortisol and aldosterone. This dysregulation is seen in 
depression and the resultant levels of norepinephrine, cortisol, and aldosterone independently 
predict mortality in HF. Vascular endothelial dysfunction and elevated inflammatory markers 
(e.g., tumor necrosis factor, interleukin-6, C-reactive protein) are present with depression and are 
associated with poor of outcomes in patients with HF (Aloisi et al., 2019; Celano et al., 2018). 
Depression, aging, and HF independently contribute to hypercoagulable blood.  
Hypercoagulability not only contributes to thrombogenesis and cardiovascular events, but also 
worsens depressive symptoms by inhibiting formation of mature brain-derived neurotrophic 




nervous system responses to inflammatory processes can also trigger fatigue and other 
depressive symptoms (Aloisi et al., 2019).  
Depression is bidirectionally associated with inflammation and both are linked to 
progression of HF (Kop, Synowski, & Gottlieb, 2011). Furthermore, exacerbations of HF can 
reduce oxygenation to the hippocampus, an important structure for neuropsychological 
functioning, and trigger a depressive episode (Aloisi et al., 2019). Therefore, it is reasonable to 
expect that a proportion of patients with HF will develop depression (Aloisi et al., 2019). Refer 
to Appendix A for the common symptomology and of both conditions.  
The problem of comorbid depression in patients with HF is complex and outcomes 
depend on a relationship between many factors. It is the provider’s responsibility to assess the 
whole patient, then prioritize and facilitate treatment. Both depression and HF can require 
combining a variety of treatment approaches. Thus, it was important for this project to include a 
treatment/referral algorithm to aid the HF specialty providers to enhance their clinical practice in 
real time.  
Conceptual Framework for Managing Adults with Chronic HF 
The Domain Management Approach to HF, based on Engel’s (1977) biopsychosocial 
construct, is a useful four-dimensional holistic framework to view the complex clinical problem 
of comorbid depression and HF (Gorodeski et al., 2018). The four domains include medical, 
mind and emotions, physical function, and social environment. This framework was developed 
to highlight the complex interactions between multiple factors that contribute to the overall 
health of patients with HF and to provide clinicians with a comprehensive and multidimensional 
assessment approach to improve health outcomes for patients with HF (Gorodeski et al., 2018).   
The medical domain aligns with a traditional biomedical approach to management and 




Relative to HF, this includes identifying the etiology of the condition (e.g., an ischemia etiology 
due to coronary heart disease [CHD] as opposed to other non-ischemic etiologies) and the 
severity of the dysfunction as measured by the ejection fraction. The mind and emotion domain 
aims to evaluate mental health and cognition. This domain is relevant to HF for treatment 
adherence, self-management abilities, and underlying mental health conditions that can effect 
outcomes and complicate treatment. The physical function domain encompasses the physical 
strength and functional capacity to perform activities of daily living, the capacity for aerobic 
activity, and the level of risk for injury (e.g., falls). This is addressed relative to HF by 
determining New York Heart Association (NYHA) HF functional class at each visit. Finally, the 
social environment domain is the patient’s physical and social living circumstances that exist 
outside the clinic or hospital setting.  Relative to HF, this targets the patient’s family and social 
support system, home environment, transportation resources, and financial resources to increase 
treatment adherence and effectiveness (Gorodeski et al., 2018).  
Based on this framework, all four domains should be addressed to adequately assess, 
manage, and care for the whole person with HF (Gorodeski et al., 2018). This framework fits 
well within the nursing metaparadigm of person, health, environment, and nursing. It is 
important for APRNs to assess patients holistically to help patients find overall wellness. This 
project primarily focused on improving HF management within the mind and emotion domain by 
incorporating depression screening, identifying patients with comorbid depression, and initiating 
an evidence-based treatment algorithm, when indicated, into the routine clinic visit assessment 
for patients with chronic HF. As a result, the other three domains, medical, social, and physical, 




From the onset, it was believed that if this project demonstrated an ability to address 
barriers to screening and provide a process (e.g., algorithm) that makes initiating depression 
treatment more efficient in this high-risk patient population, then a clinical practice improvement 
would be achieved. Through effective screening, assessment and identification, and management 
of comorbid depression, the value that APRNs have in providing holistic care to these complex 
patients is realized. Furthermore, if successful, this project would demonstrate the value of 
having APRNs in healthcare who bring the skill and knowledge of how to translate evidence into 
feasible and sustainable clinical practice.  
7 
CHAPTER 2: LITERATURE REVIEW 
Search Strategy 
Databases searched included PubMed, PsychInfo, and the Cumulative Index of Nursing 
and Allied Health Literature. Searches were limited to the English language, journal article(s), 
adult subjects, and years of publication were limited to the past 20 years. Search terms to capture 
the HF population included: “cardiac failure” or “heart decompensation” or “heart failure 
[mesh]” or “heart failure” or “cardio-renal syndrome” or MH "Heart Failure+". Search terms for 
depression included: depression [mesh] or depression or depressive or depressive disorder.  
Other search terms combined with heart failure and depression included: systematic [subset] or 
“Systematic review;” “quality improvement” [mesh] or “quality improvement” or 
"implementation science" or "process improvement" or "change management;" "guideline 
adherence" [mesh] or “guideline adherence” or “policy compliance;” screening or screenings or 
mass screening [mesh] or “depression screening;” barriers or facilitators and screening or 
screenings or mass screening [mesh] or “depression screening;” intervention or interventions or 
cognitive behavioral therapy or CBT; SSRI or selective serotonin reuptake inhibitor or 
“pharmacologic intervention;” exercise or exercise therapy or ET; consequences or untreated; 
theory or theories or theoretical or construct or mediator; random*; prevalence treatment (year 
limit 2010); prevalence; comorbid.  
In addition to using databases, an ancestry approach was taken to retrieve seminal works 
cited in the reference lists of key articles. Article sharing through professional colleagues and 




depression and HF were retrieved (e.g., American Heart Association [AHA], Heart Failure 
Society of America [HFSA], American Psychiatric Association). The total number of abstracts 
reviewed was 150, and based on the context of an abstract, the full article was reviewed; 76 
articles were included in this review of literature.  
Synthesis of Literature 
Comorbid HF and Depression 
 Heart failure afflicts an estimated 26 million people worldwide (Savarese & Lund, 2017). 
Depression and HF are two chronic conditions that often coexist. More than one in five patients 
with chronic HF have clinically significant depression (Rutledge et al., 2006). Notably, 
depression is two to three times more likely in patients with HF than in the general population 
(Kim, Shin, & Song, 2015; Kop, Synowski, & Gottlieb, 2011; Rutledge et al., 2006). Those with 
HF who are at higher risk for comorbid depression include individuals who are women, younger 
than 60 years of age, have low socioeconomic status, and have never married (Chobufo et al., 
2020).  
Three studies reviewed specifically aimed to describe the prevalence of depression 
among patients with HF. The first was an observational cohort study which found a 36% 
prevalence of depression among the 153 enrolled participants who were from the United States, 
Canada, and New Zealand (Friedmann et al., 2006).  Authors used a cut-off score of 13 on the 
Beck Depression Inventory-II (BDI-II) tool to measure for depression (Friedmann et al., 2006). 
The other two studies were observational cohort studies that used a cut-off score of ten on the 
Patient Health Questionnaire nine-item (PHQ-9) screening tool to determine depression in 
subjects (Bhatt et al., 2016; Zahid et al., 2018). While Bhatt and colleagues (2016) found 26% 
prevalence of depression in 308 participants with HF in the United States, Zahid et al. (2018) 




Furthermore, a meta-analysis conducted with data from 26 articles, including 80,627 
participants, revealed that prevalence of depression varied from 10% to 79%, with an 
approximate average of 29% (Sokoreli et al., 2016). This illustrates that results yield a wide 
range of prevalence rates of depression among patients with HF. The marked range can be 
explained by subject demographics (e.g., regional and socioeconomic variations), clinical 
characteristics (e.g., comorbidities, medication regimens), timing and frequency of depression 
screening, and the methods used to define depression (e.g., screening, diagnostic assessment, 
medical records).  
Due to the high prevalence of depression, studies have examined the association between 
depression and poor outcomes in patients with chronic HF. Two meta-analyses were reviewed, 
both indicating that depression in patients with HF was associated with higher all-cause mortality 
rates than in patients who had HF without depression. A large study by Sokoreli and colleagues 
(2016) and another meta-analysis by Fan et al. (2014), consisting of nine studies and 4,012 
participants, reported similar significant hazard ratios: 1.40 and 1.51, respectively. Both studies 
reported hazard ratios adjusted for confounding factors (i.e., age, gender, NYHA class, ejection 
fraction) and Sokoreli and colleagues (2016) conducted their study based on PRISMA 
guidelines. Chobufo and colleagues (2020) found depression in patients with HF was 
independently associated with a more than twice the risk of HF associated morbidity and 
mortality. Furthermore, Chandra and colleagues (2020) found that higher PHQ-9 scores, 
indicating worse depression symptoms, was associated with all-cause mortality and 
cardiovascular death specifically among patients with HF with preserved ejection fraction. This 
suggests depression negatively affects patients with HF regardless of their ejection fraction as 




The impact of depression on patients with HF has further been associated with decreased 
QOL, poorer self-care, increased rehospitalization rates, and higher healthcare costs. One study 
with 200 patients with HF from Jordan found depression, measured with the Hospital Anxiety 
and Depression Scale (HADS), was an independent predictor of poor QOL, based on Short 
Form-36 scores (AbuRuz, 2018). As Jordan is considered a developing country, it was uncertain 
whether these results are transferable to a United States population. However, Bhatt and 
colleagues (2016) supported these findings with a United States population by showing that 
patients with mild depressive symptoms, using the PHQ-9 tool, were 13 times more likely to 
have poor QOL measured by the Kansas City Cardiomyopathy Questionnaire and patients with 
moderate to severe depressive symptoms were 60 times more likely.     
Depression has also been shown to effect cognition, motivation, and engagement, thereby 
contributing to poorer HF self-care (Chobufo et al., 2020). Self-care is important for patients 
with HF in order to monitor HF symptoms, quickly recognize physiologic changes, and adhere to 
a treatment regimen. Freedland and colleagues (2020) found higher PHQ-9 scores (i.e.,, worse 
depressive symptoms) were independently associated with worse HF self-care. In fact, self-care 
interventions have been shown to have a positive impact on HF self-care, even in patients with 
depressive symptoms (Alosais et al., 2020) 
Rutledge and colleagues (2006) reviewed seven studies that supported increased use of 
healthcare resources in patients with comorbid depression and HF. Notable findings included a 
doubled risk of emergency department visits and a 29% increase in total healthcare costs for 
those patients with comorbid depression and HF compared to those with HF alone (Rutledge et 
al., 2006). Ishak and colleagues (2020) also found that patients with comorbid depression and HF 




In addition, two American studies sampled 662 hospitalized and 308 non-hospitalized 
patients with HF and found that depressive symptoms predicted the rate of hospital readmissions 
(adjusted hazard ratio of 1.09 and 1.57, respectively) (Freedland et al., 2016; Bhatt et al., 2016, 
respectively). Notably, the severity of depression significantly increased the risk of all-cause 
rehospitalization as the hazard ratio in major depression was 1.51 (Freedland et al., 2016) and 
1.70 in patients with moderate to severe depressive symptoms (Bhatt et al., 2016). Freedland and 
colleagues (2016) used the National Institute of Mental Health Diagnostic Interview Schedule to 
measure depression and the participants were initially hospitalized between 1994 and 1999, 
while Bhatt and colleagues (2016) used the PHQ-9 tool to measure depression and conducted 
research between 2007 and 2011. These studies used different methods to measure depression 
and, although both studies were published in 2016, it is plausible that hospitalization rates may 
have been influenced by dated HF care and management in the Freedland et al. study.  
Another study conducted in the United States included 14,902 Medicare participants’ 
healthcare costs and found significantly higher total healthcare costs in participants with 
depression and HF or diabetes ($15,750 per year) as compared to non-depressed participants 
with chronic disease ($10,673 per year) (Unützer et al., 2009). Furthermore, when costs were 
categorized, Unützer and colleagues (2009) found that specialty mental health care accounted for 
less than one percent of total healthcare costs of depressed participants. While this study is not 
specific to patients with HF, it is worth noting the presence of comorbid depression in chronic 
diseases as HF is a major, progressive, and chronic disease.   
Depression Screening in Patients with HF  
Currently, the European Society of Cardiology and the Italian Geriatric Cardiology 
Society HF guidelines recommend routine depression screening in patients with HF (Aloisi et al., 




15) screening tools (Aloisi et al., 2019). While American guidelines have not yet made specific 
recommendations for the HF population, the AHA published a science advisory 
recommendation, endorsed by the American Psychiatric Association, to minimally screen all 
patients with CHD for depression using the abbreviated Patient Health Questionnaire 2-item 
(PHQ-2) tool (Lichtman et al., 2008).  This recommendation addresses a portion of the HF 
population as approximately one half of adults with HF have CHD as an etiology.  
Furthermore, the AHA recommends a stepwise-screening approach using the PHQ-2 and 
PHQ-9 (Lichtman et al., 2008). These recommendations are Level V evidence and lack thorough 
description of the literature review completed to support these statements. In response to these 
recommendations, two systematic reviews of literature published found no studies that met the 
aim of describing the effect of screening on depression outcomes in patients with CHD (Health 
Quality Ontario, 2013; Thombs et al., 2013).  
Still, the AHA Heart Failure Management Guidelines, a Level I systematic review, note 
that depression is a common comorbidity in patients with HF and is associated with poorer 
outcomes (Yancy et al., 2013). While Yancy and colleagues (2013) state the most effective 
intervention for comorbid depression is not yet known, routine screening according to the United 
States Preventative Services Task Force (USPSTF) is endorsed as a part of HF management. 
Thus, adequate evidence exists showing that early detection of depression with support systems 
in place improves clinical outcomes and little to no harm results from screening adults for 
depression (Siu et al., 2016). 
The USPSTF recommends that clinicians choose a screening method that is most 
acceptable to the specific practice setting and population served; there is no one superior 




interval that is recommended for screening. Jha and colleagues (2019) suggest rescreening could 
be considered annually and more frequently if significant stress, change in clinical condition, or 
hospitalization has occurred. Moreover, screening during all routine health visits (e.g., routine 
HF follow-up visits) is an acceptable option that adds ease to implementation (Maurer, 
Raymond, & Davis, 2018). 
Three broad approaches have been used in research studies that identified depression in 
patients. The first broad approach, and least specific, is by retrospective chart review of patient 
medical history and prescribed use of antidepressant medication. The second broad approach is 
through clinical interview. A provider, qualified to diagnose, conducts an interview with the 
patient to assess for the DSM-V criteria necessary for a diagnosis of major depression. 
According to DSM-V criteria, major depressive disorder (MDD) can be diagnosed when at least 
five of the following symptoms have been present during the same two-week period and at least 
one of the symptoms must be diminished interest/pleasure or depressed mood: anhedonia, 
change in weight or appetite, sleep disturbance, psychomotor agitation or retardation, fatigue or 
loss of energy, feelings of worthlessness, diminished ability to think or concentrate, and recurrent 
thoughts of death or suicidal ideation (American Psychological Association, 2013).  
The third broad approach is through patient self-report screening tools. Screening tools 
are clinically useful for initial assessment to help identify patients with depression. However, 
findings need to be confirmed by clinical interview for a diagnosis, based on DSM-V criteria, to 
be established (Sbolli, Fiuzat, Cani, & O’Connor, 2020).  Findings from a recent systematic 
review by Ishak and colleagues (2020) reinforce heterogeneity among tools used to screen for 
depression in patients with HF. The PHQ-2 and PHQ-9, GDS-15, Cardiac Depression Scale 




questionnaires to screen patients for depression (Ishak et al., 2020; Liguori, et al., 2018; Siu et 
al., 2016). All of the tools take approximately five minutes or less to complete, except for the 
BDI-II which takes ten minutes. The number of items, or questions, on each tool varies from two 
to 26. While most tools use a Likert rating scale (e.g., 0-3, 0-7) for each item, the GDS-15 and 
PHQ-2 ask for a binary response (i.e., yes versus no). All of these tools have been validated in 
the general population and the PHQ-9, GDS-15, and HADS have been validated in the HF 
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The GDS-15 is a 15-item self-report screening tool that asks binary questions (i.e., yes 
versus no) based on symptoms experienced in the past one week. The tool was developed for 
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(2006), the GDS-15, with a cut-off score of six, has a 94% sensitivity and 85% specificity when 
administered to older adults with mild or moderate cognitive impairment. In this study, the GDS-
15 was verbally administered by a research assistant to 113 participants ranging in age from 65 
to 99 who lived in Australian assisted living facilities that varied in size and required level of 
care (McCabe et al., 2006).  
The PHQ-2 is a two-item self-report binary question (i.e., yes versus no) depression 
screening tool. Kroenke, Spitzer, and Williams (2003) originally reported that this tool had a 
sensitivity of 83% and a specificity of 92% and an area under the curve of 0.93 in the general 
population when using a cut-off score of three. Furthermore, while the PHQ-2 has not been 
validated in a HF-specific population, it has been in patients with stable CHD.  The PHQ-2 has a 
high specificity at 90%, with a relatively lower sensitivity of 69% using a cut-off score of one 
(Elderon et al., 2011).  
However, the PHQ-9 has been validated in the HF population with a sensitivity of 70% 
and specificity of 92% (Hammash et al., 2013). Thus, a positive PHQ-2 screening warrants 
further screening with the PHQ-9. The PHQ-9 is widely used for adults in outpatient clinics and 
recognized for its validity and feasibility. This nine-item self-report depression screening tool 
asks, on a Likert scale (i.e., not at all, some days, more than half the days, nearly every day), the 
frequency of having specific symptoms based on DSM-IV, diagnostic criteria for depression and 
other psychiatric disorders. To align with the DSM-IV MDD diagnosis, the patient is instructed 
to answer questions of frequency based on the past two weeks (Kroenke, Spitzer, & Williams, 
2001). The original research that tested validity of recognizing MDD was completed with 6,000 




(Cronbach alpha of 0.86 to 0.89), specificity (88%), and sensitivity (88%) (Kroenke, Spitzer, & 
Williams, 2001). A cutoff score of ten was used for these calculations.  
As discussed, use of the PHQ-2 and PHQ-9 in a stepwise screening approach is 
recommended by the AHA (Lichtman et al., 2008). If either question on the PHQ-2 tool is 
answered positively, further screening is recommended using the PHQ-9 tool (Lichtman et al., 
2008). The stepwise screening recommendation suggests using a cut point of ten on the PHQ-9 
informs treatment. Patients who score less than ten on the PHQ-9 should be provided supportive 
care and follow-up treatment and rescreening within one month, while those with scores greater 
than ten should promptly receive clinical evaluation to determine appropriate treatment and 
referral as necessary (Lichtman et al., 2008). Notably, the AHA emphasizes the importance of 
using the PHQ-9 as the final question specifically screens for suicidality (Jha et al., 2019; 
Lichtman et al., 2008).  
Treatment of Depression in Patients with Chronic HF  
While robust research supports a link between depression and poor outcomes in patients 
with HF, there is less definitive research that points to a single effective intervention to treat 
depression. Three of the most studied treatment approaches for depression in patients with HF 
include cognitive behavioral therapy (CBT), antidepressant pharmacotherapy, and exercise 
therapy (Das et al., 2019; Sbolli, Fiuzat, Cani, & O’Connor, 2020).  
Cognitive Behavioral Therapy 
A form of psychotherapy, CBT focuses treatment of depression on an individual’s 
patterns of thought and behavior, thus developing healthful coping skills (Jeyanantham et al., 
2017). Freedland and colleagues (2015) conducted a high-quality randomized-control trial (RCT) 
of 158 participants with chronic HF that compared CBT to usual care and yielded positive 




treatment manuals were led by experienced masters- or doctoral-prepared therapists for six 
months. The participants in the treatment arm had lower depression scores at their six-month 
follow-up and statistically significant maintenance of depression scores, mental health, and HF-
related QOL at one-year follow-up as compared to participants in the control group (Freedland et 
al., 2015).  
Furthermore, the study by Freedland and colleagues (2015) was included in a meta-
analysis with five other studies that explored the effects of CBT on depressive symptoms in 
patients with chronic HF (Jeyanantham et al., 2017). With the combined 320 participants across 
all six studies, Jeyanantham and colleagues (2017) found that depressive symptoms in the 
patients who received CBT sessions ranging from 30 to 60 minutes administered once to weekly 
for six months had significant improvement after the initial treatment and at the three-month 
follow-up, as compared to usual care. Quality of life was also assessed in the five RCTs. Across 
the studies, improvement of QOL was seen in participants in the CBT group as compared to 
those in the usual care group (Jeyanantham et al., 2017). Ishak and colleagues (2020) also 
conducted a systematic review that found support for psychotherapy as the first-line treatment 
for depression in patients with CHD. Notably, psychotherapy had the most benefit for patients 
with HF as compared to those with other forms of CHD (Ishak et al., 2020). 
However, there are limitations to CBT. While CBT has been shown to have beneficial 
effects to patients with chronic HF who have depressive symptoms, the acceptability and 
feasibility may not be sufficient for some patients. For example, accessibility varies depending 
on where the patient lives and what medical coverage they use. Many counseling services do not 
accept Medicare/Medicaid and, therefore, patients may need to increase travel distance to find a 




counseling services. Furthermore, patients with comorbid depression and HF may have physical 
and mental limitations due to their conditions that can make adding another frequent medical 
appointment to their routine a challenge.  
Antidepressant Pharmacotherapy 
Pharmacologic interventions have also been used to treat depression in patients with HF. 
However, antidepressant pharmacotherapy has traditionally been used with caution in this 
population due to the potential risk of adverse effects in this relatively sick patient population. 
Furthermore, some drug classes have been determined to be associated with less side effects as 
compared to others.  
Safety of Antidepressant Pharmacotherapy. Selective serotonin reuptake inhibitors 
(SSRIs) (e.g., sertraline, citalopram, and escitalopram) have been shown to be the safest 
pharmacologic treatment for depression in the chronic HF population (Sbolli, Fiuzat, Cani, & 
O’Connor, 2020). Historically, the Sertraline Against Depression and Heart Disease in Chronic 
Heart Failure (SADHART-CHF) RCT confirmed the safety of sertraline in patients with HF 
while the MOOD-HF RCT found that escitalopram was safe and well-tolerated among HF 
patients (Angermann et al, 2016; O’Connor et al., 2010). Rajeswaran and colleagues (2018) 
conducted a systematic review of the use of antidepressant medications, primarily SSRIs, in 
patients with chronic HF. Findings revealed no association between antidepressant use and 
increased mortality in patients with HF (Rajeswaran et al., 2018).  
Notably, SSRIs are less likely to cause orthostatic hypotension and tachycardia compared 
to tricyclic antidepressants and, in general, are associated with few cardiac side effects (Celano et 
al., 2018). This is important since many patients with chronic HF have relatively low systolic 
blood pressure (i.e., low 100s or upper 90s) due to being on beta-blockers, renin angiotensin 




rehospitalization. In addition, tachycardia could potentially decrease cardiac output for those 
with reduced ejection fraction or precipitate other arrhythmias in patients with chronic HF.   
The three most worrisome side effects associated with SSRI use in patients with chronic 
HF include bleeding, QTc prolongation, and drug-drug interactions with cardiovascular 
medications (e.g., antiarrhythmics, warfarin, angiotensin receptor blockers). Increased gastric 
acid secretion and inhibited platelet aggregation may occur with use of SSRIs which increases 
the risk of bleeding (Celano et al., 2018). Some patients with HF have comorbid atrial fibrillation 
or mechanical heart valves that required chronic anticoagulation. Therefore, the potential for 
bleeding needs to be considered when evaluating the risk versus benefit of the treatment option 
for these patients. QTc prolongation is a concern for HF healthcare providers as it can cause 
lethal ventricular arrythmias when the QTc measures 450 milliseconds or greater (normal QTc 
400 milliseconds or less). However, as a group, SSRIs increase the QTc by only 6.1 milliseconds 
with citalopram being associated with the most QTc prolongation at 10.58 milliseconds (Beach 
et al., 2014). Finally, SSRIs can affect serum drug levels of other medications that the patient is 
taking.  
 According to the AHA, sertraline and citalopram are first-line agents to treat depression 
in patients with CHD (Lichtman et al., 2008). Sertraline is often the preferred first-line choice of 
SSRI medication in patients with chronic HF given its safety as compared to other agents 
(Celano et al., 2018). Citalopram and escitalopram are additional SSRI options for patients with 
HF, although the patient-specific risk for QTc prolongation must be considered. Sertraline, 
citalopram, and escitalopram have the lowest risk of drug-drug interactions (Celano et al., 2018). 




should be initiated at low doses and titrated until remission of depressive symptoms is achieved 
(Celano et al, 2018).  
Effectiveness of Antidepressant Pharmacotherapy. A retrospective follow-up study to 
the SADHART-CHF trial compared the prevalence of cardiovascular events in participants who 
had improved depression scores and were considered “in remission” as compared to those who 
remained depressed (Jiang et al., 2011). Significantly less cardiovascular events were observed 
in patients with HF who were considered in remission of depression compared to those patients 
who remained depressed (Jiang et al., 2011). Therefore, this study showed that decreasing 
depressive symptoms using antidepressant pharmacotherapy was associated with a decrease in 
cardiac events.  
Unfortunately, research studies have had mixed results showing the effectiveness of 
antidepressant pharmacotherapy on depressive symptoms and cardiovascular status in patients 
with HF. Rajeswaran and colleagues (2018) ultimately found that, among the five studies 
included in their systematic review, antidepressant use in patients with HF did not result in 
significant improvement of cardiovascular status (e.g., NYHA class, cardiopulmonary exercise 
test) or depressive symptoms. A recent scoping review revealed that more evidence exists that 
support the efficacy of using SSRIs to treat depression in patients with CHD than in patients with 
HF (Zambrano et al., 2020). However, among the 42 RCTs reviewed, nearly 80% of participants 
had CHD and only 20% had HF, indicating more research is needed in patients with HF 
(Zambrano et al., 2020).  
Exercise Therapy 
Structured exercise training serves as an appealing treatment option for depressive 
symptoms in some patients with complex comorbidities such as HF. Initially, due to safety 




However, exercise training remains a viable treatment option for patients with chronic HF as, 
over time, research has shown the benefits of this nonpharmacologic treatment option and that it 
has a neutral effect on HF mortality and morbidity. Exercise training is now an AHA class I 
recommendation for patients with HF to safely and effectively improve functional status (Yancey 
et al., 2013). Moreover, a recent Cochrane review, which included 44 trials, found that exercise-
based cardiac rehabilitation programs reduce all-cause and HF-related hospitalizations and 
improve HF-related QOL (Taylor et al., 2019). Notably, exercise training as a nonpharmacologic 
treatment option eliminates the risk for drug-drug interactions and polypharmacy and it 
encourages active patient participation in care. Furthermore, exercise training has a potential 
positive effect on depressive symptoms as it stimulates an increase of essential mood-regulating 
neurotransmitters (e.g., serotonin, norepinephrine, dopamine) and helps regulate sympathetic 
activity and inflammatory processes (Aloisi et al., 2019). A meta-analysis by Tu and colleagues 
(2014) of 16 RCTs quantified the effects of exercise training on depressive symptoms in patients 
with chronic HF. Exercise training (e.g., Tai Chi, cycling, walking, resistance training) was 
conducted either at home or supervised and ranged from 20- to 90-minute sessions, two to seven 
days per week for six to 53 weeks. Analysis of data from 3226 patients revealed that exercise 
training, either by itself or combined with a cardiac rehabilitation program, resulted in a 
significant reduction in depressive symptoms, regardless of the specific exercise program or how 
depression was measured (Tu et al., 2014). Another meta-analysis of RCTs by Sagar and 
colleagues (2015) evaluated the effects of exercise training either alone or as a component of an 
exercise-based cardiac rehabilitation program on patients with HF. As Tu and colleagues (2014) 
also found, the exercise training was conducted either supervised or at home and with a wide 




reduced hospital admissions as compared to usual care at the 12-month follow-up. Moreover, 
pooled data from 18 studies revealed that exercise training in patients with HF yielded a 
significant improvement in QOL. The benefits of exercise training appeared to be independent of 
the type of exercise (e.g., exercise only, exercise-based cardiac rehabilitation program, aerobic, 
aerobic and strength training), amount of exercise, and length of follow-up (Sagar et al., 2015). 
Direct Comparison of Treatment Options 
Past research has also included direct comparison of various treatment options for 
depression. For example, a systematic review published by Qaseem, Barry, and Kansagara 
(2016) compared pharmacologic (i.e., SSRIs, serotonin norepinephrine reuptake inhibitors, 
bupropion, mirtazapine, nefazodone, trazadone) and nonpharmacologic (i.e., psychological 
interventions including CBT, complimentary alternative therapies including yoga and 
acupuncture, supplements including St. John’s Wort, and exercise) treatment options for initial 
management of MDD in adults. Results of the studies reviewed revealed no difference in 
response or depression remission rates when comparing sertraline to exercise training. Moreover, 
both interventions showed similar discontinuation rates. Furthermore, results revealed no 
difference in clinical response to SSRIs and other second-generation antidepressants compared to 
CBT.  
However, there were mixed results related to the use of combination therapy consisting of 
second-generation antidepressants and CBT to improve clinical response or remission of 
depressive symptoms (Qaseem, Barry, & Kansagara, 2016). Gartlehner and colleagues (2011) 
argued that combination therapy is needed for many patients with MDD since remission is not 
typically achieved after an initial treatment of a second-generation antidepressant. Therefore, 
switching therapy or adding combination therapy may be required to achieve remission 




management approaches that combine treatments methods may show more promise in 
effectively treating depression than using a single treatment modality. More multimodal studies 
are needed to test efficacy of combination treatment for depression in patients with HF.  
Ultimately, the American College of Physicians strongly recommends, with moderate-
quality evidence, that providers prescribe either second-generation antidepressants or CBT to 
treat adults with MDD (Qaseem, Barry, & Kansagara, 2016). Shared decision making should be 
used with the patient to ascertain patient preferences in consideration of weighing adverse 
effects, cost, accessibility, and patient preferences (Qaseem, Barry, & Kansagara, 2016).  
Specific to the HF population, Das and colleagues (2019) conducted a meta-analysis 
comparing CBT, antidepressant pharmacotherapy, and exercise therapy in treating depression in 
patients with HF. Results indicated that CBT and exercise therapy were associated with reduced 
depressive symptoms. Of the three treatment options, use of antidepressants was least effective 
in reducing depressive symptoms. However, authors noted that the relatively short duration (two 
to three months) of follow-up in the reviewed studies that examined antidepressant 
pharmacotherapy may have influenced the level of effectiveness (Das et al., 2019). Ultimately, 





Table 2: Depression treatment in patients with HF 
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Real-World Screening: Past Quality Improvement (QI) Successes and Challenges  
While evidence supports the need for routine depression screening and the availability of 
reliable and valid screening tools to facilitate screening, there is a gap in the literature describing 
broad-scale implementation of depression screening in the outpatient HF population. Past 
research has demonstrated successes and lingering challenges to implementing systematic 
depression screening for adults across specific patient populations in both inpatient and 
outpatient settings. Eight studies were retrieved from the literature review that reported 
implementation of depression screening: three from in-patient (hospitalized) settings and five 
from out-patient settings.  
Screening Hospitalized Patients with Cardiovascular Conditions 
Smolderen and colleagues (2011) implemented a depression screening protocol based on 
the AHA guidelines to screen (using the PHQ-2 and PHQ-9 stepwise approach) in patients who 
had been hospitalized for an acute coronary syndrome (ACS) event in 2005 in a Heart and 
Vascular Institute in Kansas City. Prior to implementation, multidisciplinary stakeholders (e.g 
clinicians, researchers, and quality managers) met to develop and finalize the stepwise 
depression screening protocol for patients who were on the ACS management pathway in their 
institute. The screening was incorporated into the ACS management pathway, thus becoming 
part of the mandated care for this patient population. Once the patient stabilized, the nursing staff 
administered the PHQ-2 to the patient (first step) to determine if they were at risk for major 
depressive symptoms. Then, if the PHQ-2 score was one or more, the electronic medical record 
(EMR) would automatically prompt completion of the PHQ-9 to be administered in real time by 
the nurse. The nursing staff then notified the provider of a positive PHQ-9 score, using the cut 
point score of ten. The provider then selected an appropriate treatment plan for the patient based 




project). The treatment plan included options such as referral to the pharmacy (to select and 
initiate an antidepressant medication), referral to social services (for outpatient treatment options, 
consultation with a chaplain while still in the inpatient setting, or referral to the in-hospital 
psychiatric service (mandatory if the patient endorses suicidal ideations). The provider 
documented the plan in the discharge summary (Smolderen et al., 2011).  
Outcomes for the project included: 1) the percentage of patients who received screening 
and the reasons for those who did not receive screening, 2) the percentage of patients who were 
screened positive on the PHQ-2, and 3) the portion who scored in each category of the PHQ-9 
(score < 5 with no depressive symptoms; score 5-9 with mild depressive symptoms, and score > 
10 with moderate to severe depressive symptoms).  
Results revealed that approximately three quarters (73.2%) of patients were screened 
using the protocol during hospitalization in a median time of one day from admission to 
depression screening. Of the 26.8% of patients who were not screened, no valid reason was 
documented for lack of screening for majority of the patients. However, if a reason for non-
screening was found, it related to either the patient being too sick for screening or the patient 
going to surgery. Those not screened were more likely to be female, had a history of acute 
myocardial infarction, angina, lung disease, or experienced an in-hospital cardiac arrest. Of those 
who were screened, one in five (20.4%) had a positive PHQ-2 screen, of which 30.1% had a 
PHQ-9 of ten or more (indicative of moderate to severe depressive symptoms). Notably, this 
percentage of patients with high PHQ-9 scores was similar to the data from the TRIUMPH 
registry (a comparison group of 3,533 patients from 23 other hospitals used as a benchmark for 
this study). In the TRIUMPH registry, about half (47.4%) had a positive PHQ-2 screen, of which 




reproducibility and accuracy than the PHQ-2, prompting authors to recommend using the PHQ-9 
exclusively for all patients, eliminating the need for a two-step screening approach. Also, of 
those patients who scored ten or more on the PHQ-9, 90.9% received further action (diagnosis of 
depression in the discharge summary, prescribed depression treatment before discharge, or 
referred for depression treatment after discharge).   
A second QI project conducted by McIntosh (2017) implemented an evidence-based 
depression screening protocol in patients hospitalized for stroke in an upstate New York 
inpatient hospital unit. Patients were excluded from screening if they were too ill to participate 
(i.e., obtunded [n=3], aphasic [n=8], demented [n=2], confused [n=3]). If the patient did not 
speak English an inpatient translator or telephone translator was used. As in the prior study with 
ACS patients, prior to implementation of the protocol a multidisciplinary stakeholder team 
convened to review the latest evidence and develop a step-by-step screening process that aligned 
with institutional policy. Staff nurses were educated on the importance of screening for 
depression in this particular patient population, the role of nurses and providers, and patient 
education including additional resources of information to provide for patients upon discharge. 
Staff nurses were also educated on how to use the PHQ-9 screening tool, who to notify about the 
results, and documentation needed. Copies of the handouts and a Screening Protocol Flow 
Diagram were posted on the stroke unit as a reminder of the protocol.  
The screening protocol consisted of the following: the PHQ-9 tool was administered by 
the registered nurse in the hospital setting once a stroke diagnosis was confirmed (by imaging) 
and the patient was stabilized; the PHQ-9 results and communication to the provider were then 
documented by the nurse in the EMR. As part of the protocol and flow diagram, a suggested 




ideations (question nine of the PHQ-9) underwent an automatic suicide assessment and inpatient 
psychiatric consultation was made.  The protocol was implemented over a six-week period 
(December 2014 to February 2015) and was followed by a retrospective review of the medical 
records in the two-week period following the implementation of the protocol. Chart audit data 
included: demographic data (patient age, race, gender), clinical data (comorbid conditions, type 
of stroke), and depression screening data (PHQ-9 score and the depression severity based on 
PHQ-9 score). The primary outcome of the study was whether the screening protocol was carried 
out as intended. Secondary outcomes examined the relationship between depression screening 
diagnoses and protocol variables (whether education was provided, treatment prescribed, and if 
the plan was documented in the EMR) (McIntosh, 2017).  
 Results indicated that, of the 95 patient records reviewed during the data collection 
period, 83.2 % (79 patients) were screened for depression at a median time of hospital admission 
to depression screening of 3.1 days. Of the 16 patients who were not screened, 50% (n =8) were 
aphasic while the other 50% were either confused (n=3), obtunded or too ill to participate (n=3), 
or had dementia (n=2). Of those who were screened, nearly half (48%) were classified as being 
depressed. Notably, 18% had a past medical history of depression at admission. Of those who 
were classified as being depressed, 100% received education and treatment for the depression. 
However, only 69% of those classified as being depressed had complete documentation by the 
nursing staff. A statistically significant relationship was found between patients who screened 
positive for depression and those who received education on stroke and depression (p=0.000), 
those with documentation by the nursing staff (p=0.002), and those who were medically treated 
for depression prior to hospital discharge (p=0.018). Not surprising, the group that was most 




15 to 19). Limitations of this study included the lack of baseline data for comparison and the 
relatively short period of data collection done after implementation of the project (McIntosh, 
2017).  
 In another study Gorini and colleagues (2020) screened all patients admitted to cardiac 
specialty units (i.e., HF, Cardiac surgery, invasive cardiology, clinical cardiology, and 
arrythmology) in an Italian hospital for depression using the PHQ-9 (and also the Generalized 
Anxiety Disorder [GAD-7] to screen for anxiety) to test the feasibility of a depression and 
anxiety symptom screening protocol. As part of the admission process, each patient received a 
paper PHQ-9 and GAD-7 screening tool to complete that was then reviewed by a clinical 
psychologist. The psychologist performed a clinical assessment on all patients who scored above 
a cutoff score of 10 for the PHQ-9 and a cutoff score of eight was used for the GAD-7.  If 
clinically indicated, patients with elevated scores were then provided personalized support 
sessions. Patients who elicited a positive response to the PHQ-9 suicidality question were 
immediately followed by a psychologist who performed a suicide risk evaluation.  
Of the 2515 consecutively patients admitted to cardiology units, 79.9% completed the 
PHQ-9 and GAD-7 screening tools. The authors did not report why patients did not complete the 
screening tools. Approximately 3% of patients scored above the cutoff of the PHQ-9, 6% scored 
above the cutoff of both the PHQ-9 and GAD-7, 9% scored above the cutoff of the GAD-7, and 
2% elicited a positive response to having suicidal ideations. Notably, patients admitted to the HF 
unit had a 2.59 higher risk (OR 2.59; CI 1.678; p <0.05) for depressive symptoms as compared to 
patients admitted to other cardiac units. Additionally, women were more likely to experience 
depressive symptoms. Moreover, higher PHQ-9 depression scores correlated with longer hospital 




Screening Outpatients in Primary and Specialty Care 
Jani and colleagues (2013) examined systemic depression screening for one year (2008-
2009) at family practices in Scotland who were incentivized by a national program to conduct an 
annual comprehensive health assessment for all patients with history of CHD, diabetes, or stroke. 
The one hour-long health assessment was conducted and documented by a nurse and included 
depression screening using the Hospital Anxiety and Depression Score (HADS-D) as part of the 
overall health assessment. A treatment algorithm recommended that patients with HADS-D 
scores of 11 or more be referred for CBT or pharmacotherapy. Referrals were initiated by either 
the nurse who completed the assessment or by the provider who reviewed the health assessment, 
depending on the individual practice protocols. The authors did not elaborate on whether 
screening was done by hard copy or electronically and how the results were communicated to the 
provider.  
Results revealed that of the 125,143 patients who met criteria for the annual health 
assessment, 10,670 (8.5%) were already being treated for depression, thus exempt from 
screening. Of the remaining patients who had data collected retrospectively, 31% (35,537) were 
screened for depression (as part of the overall one-hour health assessment). Of those screened, 
nearly one in five (19.9%) had HADS-D scores of greater than eight, with the majority indicative 
of mild depression (scores between eight and ten). Possible explanations offered by the authors 
for the markedly low percentage of screening (despite incentives) included provider factors such 
as lack of confidence in the screening tool or belief that depression screening does not lead to 
improvement in clinical outcomes (Jani et al., 2013).    
 Another QI project by Aleem and colleagues (2015) revised depression screening in two 
outpatient adult primary care practices in a rural academic healthcare system in New Hampshire 




multidisciplinary stakeholder group (physicians, nurses, care coordinators, representatives from 
psychiatry, general medicine, family medicine, and pediatrics). Changes in the screening process 
included using a reliable valid screening tool(s), EMR redesign including optimization of data 
entry into the EMR, follow-up of positive depression screens, and broad scale staff training.  
In brief, the screening process included providing a paper PHQ-2 and PHQ-9 tool for the 
patient to self-administer while waiting for their appointment. Different colored sheets 
containing the PHQ-2 and PHQ-9 were used by staff to indicate if the patient had completed the 
surveys in the last 30 days versus not. The “flow staff” (e.g., nurse, medical assistant) then 
entered the PHQ-2 response data into the EMR (EpicCare®, a specific EMR vendor) to be 
scored automatically. By standardizing the threshold for PHQ-2 branching, if the PHQ-2 score 
was three or greater, through the EMR, the system automatically branched out to the PHQ-9 and 
calculated a score. Additionally, through use of the EMR screening template, PHQ-2/9 data were 
automatically imported into the provider’s note thereby increasing documentation efficiency. 
Other aspects of the project included designation of roles among staff (i.e who collects data 
versus who enters data) and integrating other clinician roles into the treatment plan. Pre-set goals 
for the project included: increasing depression screening with the PHQ-2 from the baseline 
(17%) to at least 50% of visit encounters and ensuring that at least 90% of patient encounters that 
had a PHQ-2 score of three or more have a documented PHQ-9. 
Results from 41,539 patient encounters between September and April 2014 revealed that, 
after two time periods (9/9/2013-10/28/2013 and 11/4/2013-4/21/2014), depression screening 
rates increased from 17% (at baseline) to 75.9% (p <0.001). The PHQ-9 completion rates for 
those with a PHQ-2 score of three or more initially dropped from the baseline (100%) to 88.4%, 




screening method and optimizing the EMR workflow for documentation and data entry, the QI 
project goals were met (Aleem et al., 2015).  
Peters and colleagues (2020) also conducted a QI project implementing universal 
depression screening at an outpatient heart transplant clinic at the University of Colorado. Project 
goals were to improve depression screening rates from a baseline of less than 2% to 75% or 
more. During the clinic check-in process the transplant nurse coordinators completed and 
documented the PHQ-2 (embedded within the EMR). Notably, the PHQ-2 was added to a pre-
existing check-list used for each patient. The PHQ-9 was administered by the same nurse to 
patients with PHQ-2 scores of three or more. Patients with a PHQ-9 of ten or more received a 
one-page mental health resource guide that was embedded in the EMR for ease of access and 
individualization. A follow-up phone call was conducted by a cardiology NP within one week, 
one month, and three months after the elevated score. Additional options for intervention 
included referral to primary care, mental health services, and initiation or titration of medication. 
Patient engagement in mental health follow-up (i.e scheduling follow-up with primary care or 
seeking mental health services) was also measured for patients with elevated PHQ-9 depression 
scores (Peters et al., 2020).  
Results from the 11-month data collection period of the project revealed that screening 
was completed for 93% of the 834 patient visits. Only five percent (n=40) of patients had 
elevated PHQ-2 scores; all of these patients were subsequently screened using the PHQ-9 and 
82.5% (n=33) of those patients had scores that indicated moderate or severe depressive 
symptoms. At three months, 97% of patients with an elevated PHQ-9 were receiving mental 
health care, indicating high patient engagement (Peters et al., 2020). Notably however, it 




phone calls were assigned to the cardiology NP, compliance was 100% as compared to 82% 
when follow-up was assigned to the transplant social worker. Reasons for noncompliance by the 
transplant social worker(s) included it not being in their job description, time constraints, and not 
remembering. Another challenge was that not all patients with elevated scores received the 
mental health resource guide. Although the staff found that the resource to be useful, it was not 
viewed as being applicable to every patient. In addition, at times staff forgot to add the resource 
to the patient’s after-visit summary (Peters et al., 2020).  
In a fourth study, Russomagno and Waldrop (2019) implemented a standardized post-
partum depression screening schedule and referral algorithm in a rural primary care pediatric 
outpatient practice in North Carolina. As in the other studies, preplanning with various 
multidisciplinary stakeholders in addition to EMR adaptations to ensure the required 
documentation that was acceptable to staff. The project leader met with the nurses and providers 
(separately) to education and engage them in the process. A self-administered screening tool (the 
Edinburgh Postnatal Depression Scale) was distributed at appointment check-in. Nurses verified 
distribution, documented that it was distributed and, if not, the rationale. Then, the provider 
scored and documented the score including the recommendation for referral, as appropriate, in 
the EMR. The new protocol was implemented over a four-month period (September 2017 to 
January 2018) which included weekly monitoring and checking in with staff for feedback. Data 
were collected for a 12-week period before implementation of the protocol and for four months 
(17.5 weeks) following screening implementation. Outcomes of the study included the number 
and type of well visits and administration of the screening tool, the number of positive and 




 As compared to baseline (1 month before intervention), screening rates pre and post 
increased from 33% to 80% (p < 0.001). Positive screening results varied between 7% to 12% by 
type of well-child-check (e.g., 2-week, 1-month, 6-month), while referral rates for those who 
screened positive increased from 66% at baseline to 79% in the 17.5-week post-implementation 
phase (p= 0.7) (Russomagno & Waldrop, 2019). Reasons for not screening included mother not 
present during visit (n= 18), mother’s refusal (n=9), and other/documentation blank (n=2). 
Documented reasons for not being referred included the mother already receiving help (31%), 
already had a list of counselors (7.7%), and mother’s refusal (7.7%).  
 In a fifth and final study, Berge and colleagues (2019) conducted a cross-sectional study 
to assess screening methods for depression and anxiety in a Norwegian outpatient cardiology 
clinic. Subjects were recruited from the inpatient cardiology department (n=173) and the 
outpatient cardiology clinic (n=57). Subjects recruited during hospitalization were screened by 
phone one-month post-discharge by a clinical psychologist with the PHQ-2, GAD-2, and PHQ-
SADS (i.e., have you had an anxiety attack in the past month?). Outpatients were screened by a 
cardiologist or a nurse during their routine cardiology visit. Patients with elevated PHQ-2, GAD-
2, and PHQ-SADS scores were administered the HADS tool orally by a clinical psychologist. 
Counseling sessions with a clinical psychologist were then offered to those who scored four or 
more on the HADS.    
 Results showed that 25% (n=57) of the those surveyed had elevated PHQ-2, GAD-2, or 
PHQ-SADS (Berge et al., 2019). Of those, 73% (n=41) had elevated HADS scores. Notably, 
47% (n=17) patients revealed that their mental health symptoms made it more difficult to adhere 




participate in the study. However, not all providers in the clinic participated in the study with 
high workload cited as one reason patients were not invited (Berge et al, 2019).  
Lessons Learned from Studies Implementing Depression Screening 
Eight studies reviewed implemented depression screening across a specific adult patient 
population. Study populations included three inpatient settings (post ACS, post-stroke, and all 
cardiac units) and five outpatient settings (two in primary care, one in a primary care pediatric 
clinic, one in a cardiology clinic, and one in a heart transplant clinic). Six of the eight studies 
implemented depression screening prospectively as a process improvement, while two studies 
used retrospective data to evaluate a process that had been previously implemented. All eight 
studies implemented a standardized process for screening including the use of validated 
screening methods.  
Patient Populations. Patient populations included adults post-ACS (Smolderen et al., 
2011), post-stroke (McIntosh, 2017), post-heart transplant (Peters et al., 2020), post-partum 
(Russomagno & Waldrop, 2019), and those with cardiac disease (Berge et al., 2019; Gorini et al., 
2020), chronic disease (CHD, diabetes, or stroke) (Jani et al., 2013), and primary care patients 
(Aleem et al., 2015). 
Screening Tools Used. Four implementation studies used a step-wise approach starting 
with the PHQ-2 (Aleem et al., 2015; Berge et al., 2019; Peters et al., 2020; Smolderen et al., 
2011) to screen for depression. Then, if indicated, three of those studies followed with the PHQ-
9 (Aleem et al., 2015; Peters et al., 2020; Smolderen et al., 2011), while one followed with the 
HADS (Berge et al., 2019). Four studies used one screening tool, thus avoiding a step-wise 
approach: Two used the PHQ-9 (Gorini et al., 2020; McIntosh, 2017), one used the HADS-D 
(Jani et al., 2013), and one used the Edinburgh Postnatal Depression Scale due to the specific 




Administering the Tools. Four of eight studies used nursing or medical assistant staff to 
verbally administer the screening tool (Jani et al., 2013; McIntosh, 2017; Peters et al., 2020; 
Smolderen et al., 2011). Three of eight studies had patients self-administer the tool using a hard 
copy (Aleem et al., 2015; Gorini et al., 2020; Russomagno & Waldrop, 2019). In one study, 
screening cardiology inpatients and outpatients was verbally administered by a clinical 
psychologist or cardiologist (Berge et al., 2019).  
Three studies had nursing staff document responses into the EMR as they orally 
administered the screening tool (McIntosh, 2017; Peters et al., 2020; Smolderen et al., 2011). 
One study had nursing staff transcribe responses from the paper tool into the EMR prior to the 
patient being seen by a provider (Aleem et al., 2015). One study had nursing staff document 
screening completion, while the provider scored and documented responses and findings 
(Russomagno & Waldrop, 2019). Three studies did not specify how screening results were 
documented (Berge et al., 2019; Gorini et al., 2020; Jani et al., 2013).  
Essential Elements of Screening Protocols. Based on the evidence, collectively, three 
elements emerged as being essential for success by authors of the implementation studies 
discussed. The first essential element related to the need for a standardized screening protocol 
and a clinical support algorithm for treatment/referral. Copies of this information was given to 
participating staff. McIntosh (2017) additionally posted the protocols and provided patient 
resource information in staff breakrooms and restrooms. Key information provided by these 
resources included: who was responsible for administering and documenting depression 
screening, how and where to document, when screening was to take place, and what to do for an 
elevated score. For example, McIntosh (2017) noted that use of a standardized protocol and 




staff who carried out the screening and follow-up care processes. Three studies (Aleem et al, 
2015; McIntosh, 2017; Russomagno and Waldrop, 2019) used a decision flow chart which 
illustrated the screening process and how staff were to respond based on the depression screening 
score. Authors of five of the studies noted that they met with staff at the beginning of project 
implementation to provide education, discuss expectations, and clarify staff roles and 
responsibilities (Aleem et al, 2015; McIntosh, 2017; Peters et al., 2020; Russomagno & Waldrop, 
2019; Smolderen et al., 2011).  
The second essential element that was present included optimization of EMR charting 
infrastructure to provide automated decision support, enhance process workflow, and facilitate 
documentation and patient follow-up. For example, Aleem and colleagues (2015), Smolderen et 
al. (2011), and Peters et al. (2020) all used a depression screening tool that was embedded in the 
EMR. McIntosh (2017) also noted that optimizing EMR workflow made it easier to locate where 
to document, provided automatic scoring including automatic drop-down features to trigger 
subsequent questions or orders which collectively were beneficial to screening implementation 
and time saving for staff and providers. Moreover, Jha and colleagues (2019) note incorporating 
self-report assessments into the EMR can facilitate screening compliance and clinical decision 
support (e.g., “best practice alerts”) can help guide providers to initiate interventions for elevated 
scores or a positive suicide screen. Furthermore, Peters and colleagues (2020) also embedded a 
mental health resource guide for patient education into the EMR so it could be included in the 
after-visit summary for patients with elevated depression scores.  Moreover, Peters and 
colleagues (2020) added a reminder to screen onto an existing checklist; the screening task was 





The third essential element that resonated was the need to adequately ensure proper 
intervention and follow-up for patients who have significant depressive symptoms as identified 
by screening and subsequent clinical assessment. One way to address this was to develop a 
resource list to aid in treatment and referral of patients identified as having depressive symptoms. 
Waldrop and colleagues (2018) noted that a referral resource list increased staff confidence to 
screen and provided quick and easy access to knowledge of local and emergency services 
available to meet the needs of the patient in real-time. This resource list included, for example, 
contact information for local mobile crisis teams, county crisis centers, emergency departments, 
and a comprehensive list of outpatient mental health services for the area (e.g., psychiatrists, 
psychologists, therapists). Russomagno and Waldrop (2019) noted that their clinical practice 
change success was aided by use of a resource list that identified community mental health 
resources to which those with positive screening results could be referred. Berge et al. (2019) 
and Peters et al. (2020) both noted the importance of identifying staff responsible for follow-up 
and providing staff with a protocol to follow for intervention and patient follow-up.  
Challenges Faced and Potential Solutions. Several challenges were noted by authors of 
the eight studies reviewed that implemented depression screening. Challenges to implementation 
related to documentation, process complexity, provider and staff knowledge and beliefs, time 
constraints and competing patient priorities, and patient receptivity for depression screening.  
 Incomplete or inefficient documentation is as a challenge for depression screening. 
Incomplete documentation can lead to inadequate treatment and referral for depressive 
symptoms. For example, in one study, although the nurse documented the PHQ-9 score for 
hospitalized post-stroke patients, there was lack of clear provider documentation in the medical 




screened positive for depression (McIntosh, 2017). In the study, nearly half (49%) of depressed 
patients (screened positive on PHQ-9) did not have documentation of further treatment or 
referral as appropriate.  
Possible solutions include optimization of EMR documentation workflow with automated 
decision support to facilitate treatment and seamless workflow between providers. Aleem and 
colleagues (2015) recommended augmenting EMR decision support by using standardized, 
visible and meaningful embedded psychiatry resources to assist with adequate treatment and 
referral for patients with elevated depressive symptoms. This decision support could be an EMR 
alert with easy click-options for psychiatric or social work referral that is automatically 
generated when a documented depression screening score is above the set cutoff (e.g., ten for 
PHQ-9). An automated template with click-options for pertinent assessment findings and 
treatment options that providers can use to document how positive depression screens were 
further assessed and addressed would also help ensure that proper care follow-up care is 
initiated.   
Inefficient documentation can also impede process workflow and lead to poor screening 
compliance. For example, direct data entry into the EMR by clinicians during the real time 
screening eliminates a step of converting hard copy data into the EMR.  Peters and colleagues 
(2020) noted that this implementation decision helped improve screening compliance. Aleem and 
colleagues (2015) advocated for EMR optimization to streamline data entry, storage, display, and 
reporting. This could include embedding the specific screening tool template with automatic 
scoring within the EMR. Purposefully placing the screening tool documentation in a location that 
is easy for the end-user to visually see and decreasing the number of key strokes or clicks needed 




generate reports based on the screening score data entry point could improve tracking, patient 
follow-up and screening compliance.   
Process complexity challenges arose during implementation especially when the 
workflow required multiple steps, multiple personnel, or if follow-up communication required 
further action that was individualized based on the patient’s screening results and assessment. 
Smolderen and colleagues (2011) found using the stepwise screening approach (PHQ-2 and, if 
positive, PHQ-9) was challenging because adding the second tool required an additional process 
step. Therefore, authors advocated for simplification of the protocol by using the PHQ-9 alone to 
potentially increase rates of depression detection by a more comprehensive screening tool and to 
improve staff compliance by removing one step in the process.  Robust initial staff education, 
reinforcing education over time, and providing support to staff throughout implementation would 
help counteract complexity and lead to increased process compliance (Aleem et al., 2015; 
McIntosh, 2017; Smolderen et al., 2011).  Other ways to improve compliance could include 
providing staff feedback though process performance metrics (i.e., graphs of compliance rates), 
using multiple methods of staff communication (e.g., emails, posters, huddles), and seeking 
stakeholder input throughout implementation (Aleem et al., 2015; McIntosh, 2017; Smolderen et 
al., 2011).   
Provider and staff knowledge and beliefs regarding the effectiveness of screening tools 
and whether systematic screening improves health outcomes were noted to influence the success 
of implementation. Jani and colleagues (2013) noted that providers were less compliant using a 
tool they thought was less accurate than other possible tools. Additionally, if providers did not 
believe that screening for depression would improve health outcomes, they were less compliant 




showing treatment of depressive symptoms increase survival for patients with cardiac disease 
contributes to why providers have not adopted screening into routine practice. Thus, education 
for staff and providers should emphasize the high prevalence of depression in patients with HF, 
the interconnectedness of behavioral and biological mechanisms, the negative patient outcomes 
associated with depression, and the benefits of a holistic approach to patient care.  
Competing priorities and time constraints were identified as barriers to depression 
screening, especially for inpatient populations that had relatively short hospital stays (Berge et 
al., 2019; Smolderen et al, 2011). These challenges have also been noted by NPs during routine 
outpatient depression screening. In a qualitative dissertation by Chieka (2017), 16 NPs from 
primary care and cardiology specialty clinics were interviewed to determine provider perceptions 
and practices for depression screening in patients with HF. Nearly one in five (18.8%) of the NPs 
reported not screening at all because they had “more pressing concerns” to address or “not 
enough time” to screen for depression during the patient visit.  
To relieve some of the time burden for providers, screening and documentation of 
screening could be delegated to the nurse or medical assistant during initial patient intake prior to 
seeing the provider. This may be especially helpful in primary care settings where time 
allocation for appointments is shorter as compared to specialty care settings (e.g., 20-minutes vs. 
30-minutes, respectively).  
A final challenge to implementation of depression screening identified by authors related 
to patient receptivity to screening. Some patients may associate stigma with discussing mental 
health and may not endorse symptoms of depression even if asked (Chieka, 2017; Jani et al., 
2013). Possible solutions to addressing stigma include the use of common language (e.g., feeling 




2014). In addition, discussing depression in the context of other medical conditions (e.g., 
“feeling down can effect how to manage your HF and your response to treatment”) may help 
decrease or avoid feelings of stigmatization related to endorsement of depressive symptoms 
(Vieira, Brown, & Raue, 2014). Likewise, shifting language to reframe depression as a chronic 
neurological disease may increase patient acceptability of screening and provide a more 
conducive environment for endorsement of depressive symptoms (Vieira, Brown, & Raue, 
2014). Finally, providing patient and family education about biological mechanisms, risk factors, 
and consequences of depression in plain language may help patients better understand the 
importance of screening.  
Lessons Learned from Real-World Screening Studies 
There is a gap in the literature describing broad-scale implementation of depression 
screening in the outpatient HF population. However, depression screening has been successfully 
implemented in other patient populations and settings. From the literature reviewed, inpatient 
screening compliance ranged from 73.2 to 83.2 percent post-implementation (Gorini et al., 2020; 
McIntosh, 2017; Smolderen et al., 2011). Outpatient screening compliance ranged from 75.9 to 
93 percent post-implementation (Aleem et al., 2015; Peters et al., 2020; Russomagno & 
Waldrop, 2019). One outpatient study (Jani et al. (2013) reported much lower screening 
compliance (31%); however, this study was a retrospective evaluation of a preexisting screening 
process. Implementation periods generally ranged from seven weeks to one year (Aleem et al., 
2015; Gorini et al., 2020; Jani et al., 2013; McIntosh, 2017; Peters et al., 2020; Russomagno & 
Waldrop, 2019). Smolderen et al. (2011) reported data from hospital screening for a three-year 
period.  
There was compelling rationale for using the PHQ-9 alone based on data from Smolderen 




PHQ-2. This is not surprising considering nine items versus two are used to detect depressive 
symptoms. Therefore, it is reasonable to start with the PHQ-9, which also simplifies the 
screening process and is less likely to miss patients with depressive symptoms (false negatives).  
Three essential elements emerged as strategies for successful depression screening 
implementation. These included use of: 1) a standardized screening protocol, 2) embedded EMR 
automation to optimize workflow, data entry (e.g., integrate screening tool and scores), and 
decision support to prompt provider assessment and treatment, and 3) an established process for 
treatment and referral (e.g., resource/referral list) including plans for follow-up. Several 
challenges to implementation were also identified including documentation issues, process 
complexity, provider and staff knowledge and beliefs, time constraints and competing patient 
priorities, and patient receptivity to depression screening. Simplifying steps within the screening 
protocol, optimizing EMR documentation workflows and decision support, reinforcing staff 
education, incorporating stakeholder input, and using communication pearls are strategies 
suggested to address these challenges.  
Summary of the Evidence Reviewed 
Comorbid depression among patients with HF is a significant problem due to increased 
prevalence as compared to the general population and being associated with poor outcomes 
including an increased risk of mortality, healthcare costs, and decreased QOL. Professional 
organizations recommend regularly screening for depression in patients with HF (although 
frequency of interval screening is not specified). Several depression screening tools are available 
for use that are reliable, valid, and acceptable, including use of the PHQ-9, that is widely 
accepted and used to screen for depression in the outpatient population.  
The three most common treatment modalities for comorbid depression in patients with 




disadvantages for each type. For example, CBT has been shown to be effective in treating 
depression while eliminating the potential side effects of pharmacological treatment. However, 
cost, availability, and time may be barriers to CBT. Use of selected pharmacotherapy to treat 
depression in patients with HF has led to some improvements in depressive symptoms and QOL. 
Pharmacotherapy, specifically SSRIs, have been shown to be shown to be generally well-
tolerated and safe for use in patients with HF. However, patients with HF are on multiple 
medications and may opt out of adding another medication. Exercise therapy is safe for patients 
with chronic HF and has been show to decrease depressive symptoms and increase QOL without 
the risk for drug-drug interactions and polypharmacy. However, some patients may have limited 
access or time constraints disallowing use of exercise therapy as a viable option. Ultimately, 
pharmacotherapy has been shown to be the least effective treatment compared to CBT and 
exercise therapy in managing depression in patients with HF (Das et al., 2019). Thus, providers 
should implement shared decision making with the patient and caregivers, as appropriate, to 
incorporate patient values and preferences to determine next steps, including whether 
combination therapy could be used.   
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CHAPTER 3: METHODOLOGY 
Conceptual Framework 
Deming’s Plan-Do-Study-Act (PDSA) model is an iterative four-part interrelated rapid-
cycle of actions that has further evolved into a part of the Associates in Process Improvement’s 
Model for Improvement (Moen & Norman, 2010). The Institute for Healthcare Improvement 
currently uses the PDSA model to guide quality improvement (Institute for Healthcare 
Improvement, 2019). The model provides step-by-step instruction for action along with visual 
representation for a concept. First, the model requires the implementor to answer the following 
questions: What are we trying to accomplish? How will we know that a change is an 
improvement? What change can we make that will result in improvement? This helps set a clear 
aim with measurable outcomes.  
Based on the model, each PDSA cycle is repeated, theoretically indefinitely, until a 
sustainable goal has been met. Planning, involves forming a theory of an intervention that will 
produce a change and how to measure that change. Doing, involves implementing that 
intervention on a small scale and gathering outcome data. Studying, involves evaluating the 
intervention and outcome data and making modifications as needed. Acting, involves applying 
modifications to the intervention and implementing this to create a sustained quality 
improvement (Anderson, 2018).  
While the PDSA cycle was originally designed for the manufacturing industry, it is 
frequently used today throughout healthcare and nursing. The PDSA model is a valuable 




change to create quality and process improvement. Use of this model encourages small-scale, 
repetitive cycles to test interventions and make rapid assessments and changes based on results to 
make a successful process improvement (Taylor et al., 2014). For example, Hountz and 
colleagues (2017) used Deming’s PDSA model as a guiding framework to increase colorectal 
cancer screening in a nurse-managed primary care clinic. The PDSA model helped Hountz et al. 
produce positive results by emphasizing staff input and feedback which has been shown to 
improve morale and organizational effectiveness. This aspect of the PDSA cycle was particularly 
important for the current DNP project as it helped staff buy in to a student-led project that added 
a new process to the current clinic workflow. Additionally, this model provided visual structure 
that enhanced the overall organization and transparency of the project. This highly visual model 
also helped communicate process, plans, and outcomes to stakeholders and will aid in future 
reproducibility.  
Therefore, the PDSA cycle set a foundation for this DNP project. Project planning, 
implementation, and the timeline were structured around four PDSA cycles, each lasting 
approximately three weeks. Prior to the initial implementation cycle, process planning and staff 
education were conducted. The first two weeks of each cycle entailed the doing phase of the 
PDSA cycle. The planned process implementation was then carried out and the outcome data 
points were measured (studied) daily and complied. The final week of each cycle was reserved 
for studying outcomes, obtaining process feedback, and creating a plan for re-implementing with 
identified modifications (acting).   
Project Design 
This was a QI project aimed to improve patient care by implementing a practice behavior 
change primarily targeting an APRN provider. Using this design, evidence-based literature was 




process that guides discovery and implementation of quality processes and outcome indicators in 
healthcare to improve the health of the community (Bonnel & Smith, 2018). Thus, it was a fitting 
design for this project. As noted by Bonnel and Smith (2018) this design can help engage staff to 
take accountability to provide more effective care, which was applicable to this project. 
Additionally, using a team approach, evaluating the project, and providing feedback to the team 
is essential to quality improvement (Bonnel & Smith, 2018). 
For this project, APRN providers at an outpatient cardiology clinic enhanced their 
holistic approach to care by adding a psychological component to their assessment of patients 
with chronic HF that could lead to improved patient care and outcomes. As an APRN-driven 
practice change, the focus was on optimizing patient wellness as part of managing chronic 
illness. In addition, because some providers struggle to integrate current evidence into routine 
patient care (Stanik-Hutt, 2016) APRNs can help bridge that gap. Evidence needs to be 
incorporated into care protocols through a streamlined process that is easily implemented into 
practice. Application of evidence-based care is one way that APRNs can improve clinical 
outcomes (Stanik-Hutt, 2016).  
Participants 
Project participants included two APRNs who were board-certified adult NPs who cared 
for patients with chronic HF at the clinic. The target patient population was adults with chronic 
HF who were either new or established patients to the clinic. This included patients with 
preserved ejection fraction as well as those with reduced ejection fraction. Patients who 
presented to the clinic in acute HF decompensation or with a mechanical assist device were 
excluded from the project. The NP providers were allowed to exclude a patient from screening if 
they gave a reason based on clinical judgement (i.e., patient with dementia followed every three 




Patients who had been screened by the cardiology clinic using the PHQ-9 within three months of 
their visit encounter were excluded.  
Consent  
The project purpose and outcomes were described at a meeting with two APRNs who 
were nationally board-certified NPs and employed at the clinic setting being used. These NPs, 
who care for patients with chronic HF, verbally agreed to participate in this project.  
Ethical Considerations 
This project was presented to the University of North Carolina (UNC) at Chapel Hill 
Institutional Review Board prior to implementation. The review board deemed this project to 
meet non-human subjects research requirements.  
Setting  
The UNC Heart Center at Meadowmont was the setting for this DNP project. The UNC 
Heart Center is a 7,000 square-foot tertiary care referral center that includes 20 exam rooms, five 
procedure rooms for echocardiogram and stress test, and a phlebotomy laboratory. In this 
outpatient clinic setting, a highly specialized team of cardiology providers have approximately 
150 visits per month of patients with chronic HF. Types of cardiology specialists include HF, 
heart transplant, cardiac electrophysiology, and interventional and structural cardiology. This 
group of providers is part of a multidisciplinary team that include social work, psychology, 
pharmacy, nursing, medical assistants, and business administration. Services at the clinic include 
education on the management and prevention of cardiovascular disease and HF, and diagnostic 
tests such as electrocardiogram, echocardiogram, treadmill stress test, stress echocardiogram, 





For this project, the PHQ-9 tool was selected to screen patients with chronic HF for 
depression. The PHQ-9 is a nine-item self-report screening tool that asks, on a four-point Likert 
scale, the frequency of having specific symptoms based on DSM-IV diagnostic criteria for 
depression and other psychiatric disorders. To align with the DSM-IV major depression 
diagnosis, the patient is instructed to answer questions of frequency based on the past two weeks 
(Kroenke, Spitzer, & Williams, 2001). As discussed in the review of literature, this tool has 
excellent internal reliability, sensitivity and specificity. Additionally, the PHQ-9 reliability and 
validity has been established specifically in the HF population: Results from past studies have 
yielded good internal validity (Cronbach alpha of 0.83), sensitivity (70%), specificity (92%), and 
association with the BDI-II (Spearman’s rho of 0.80) (Hammash et al., 2013). Similarities 
between cardiac related and depression symptoms may explain some of this variability and 
highlights why a healthcare provider must review the completed screening assessments and 
provide further patient evaluation to confirm findings.  
The PHQ-9 is highly acceptable in an outpatient clinic setting as it is notable for its ease 
of use, takes less than five minutes for the patient to complete, is available in multiple languages, 
and has public domain, making it free for clinics to administer (Bhatt et al., 2016; Jha et al, 
2019). Moreover, at the setting for this DNP project, the PHQ-9 is built into the clinic EMR, 
includes automatic scoring, and can be easily added to staff charting flowsheets for accessible 
documentation. See Appendix B for the full PHQ-9 screening tool and how the tool is displayed 
for charting in the clinic EMR.  
The last question of the PHQ-9 screens for potential suicidality by asking the frequency 
of having “thoughts that you would be better off dead or hurting yourself in some way.”  A 




determine suicide risk and a plan of care. The P4 Suicidality Screener consists of four questions 
(i.e., past attempts, plan for suicide, probability of completing, preventative factors) to assess 
level of suicide risk. For this DNP project, this tool is also built into the clinic EMR and can be 
easily added to staff charting flowsheets for accessible documentation if a patient elicited a 
positive response to suicidality. See Appendix C for the P4 Suicidality Screener tool.  
Use of the P4 tool is supported by work from Dube and colleagues (2010) who reviewed 
two trials that examined the effectiveness of the brief P4 Suicidality Screener tool. Patients were 
assessed during five encounters over the course of one year. Of the 250 patients with comorbid 
depression and chronic pain and of the 309 patients with comorbid depression and cancer, about 
one in six triggered a suicide assessment, initiating use of the P4 tool. The P4 tool findings 
stratify the suicide risk into minimal, lower, and higher risk. The percentage of patients who 
were stratified as high risk for suicide was small: 0.4% for patients with chronic pain and 1.6% 
for patients with cancer. There were no suicide attempts or completions recorded for any patients 
in these trials. The most common preventative factors included family, future hope, faith, and 
fear of a failed attempt (Dube et al., 2010).  
Several other depression screening tools were examined and subsequently excluded from 
use in this project. The PHQ-2, as previously discussed, while not validated in a HF-specific 
population, has shown a relatively low sensitivity (69%) in patients with stable CHD. Moreover, 
if a patient scores three or higher using the PHQ-2, further screening with the PHQ-9 is 
necessary. A previous implementation study noted decreased sensitivity in the PHQ-2 compared 
to the PHQ-9 and that the stepwise screening approach increased the process complexity and, 
therefore, could have potentially decreased process compliance (Smolderen et al., 2011). 




While the BDI-II screening tool has been used for patients with HF, Friedmann and 
colleagues (2006) found it measures some symptoms that are similar to those of HF and could 
cause altered results based on the patient’s current HF status. Thus, the authors suggested that the 
PHQ-9 may be more appropriate to use in the HF population (Friedmann et al., 2006). 
Furthermore, the BDI-II is under copyright and requires a fee per use. The HADS is also under 
copyright and has fees associated with use. Therefore, it was not feasible to use the BDI-II or the 
HADS tools for this DNP project.  
The GDS-15 was another tool examined. The specific cardiology clinic patient 
population for this project has an age range of adults that is wider than that of the GDS-15 target 
population (adults 55 and older). This clinic population is younger than other similar outpatient 
cardiology clinics because it is a tertiary clinic that receives referrals for HF management from a 
wide geographical area including all of North Carolina and parts of South Carolina and Virginia. 
Therefore, the GDS-15 was ruled out for use in this project in an effort to use one screening tool 
that can accommodate all of the clinic’s patient population.  
The Hamilton Depression Rating Scale (HDRS) is a clinician-rated patient interview that 
takes 20 to 30 minutes to complete. This tool requires more education for providers to learn how 
to administer the screening than other tools available. Additionally, this tool is too time intensive 
to complete during a routine cardiology clinic visit. For these reasons, the HDRS was eliminated 
for use in this project. Another tool, the Cardiac Depression Scale (CDS) has 26 items that are 
scored using a scale ranging from zero to seven and has a possible score of 26 to 182. This wide 
range of scoring was seen as a possible barrier as scoring could become cumbersome for the 





 As this was an APRN-driven process improvement, one of the two clinic NPs who cared 
for patients with chronic HF acted as the on-site project champion. The identified champion 
partnered with the clinic’s LCSW and psychologist to facilitate a process to address patients with 
positive depression screenings. Other clinic staff including providers, nurses, medical assistants, 
office staff, and clinic pharmacist played a role in the implementation and success of this project. 




First, the project and rationale were vetted through the NP champion, LCSW and 
psychologist. With support from these key roles, the project was introduced to the whole clinic 
during a staff lunch-and-learn meeting. Project implementation began with two weeks of staff 
education specific to each member’s role in the practice change. Education was facilitated by the 
student investigator (Elizabeth Wilhelm). The cardiology clinical psychologist (Dr. L. Rossman) 
supported staff education by emphasizing the relevance of this project and providing clinical 
pearls for how to approach and discuss depression and depression screening with patients. The 
two NP providers received the most intensive education of all the staff including how to interpret 
scores, DSM-IV major depression disorder diagnostic criteria, suggestions for patient receptive 
dialogue (i.e., normalizing mental health care in words the patient understands), how to utilize 
depression algorithm and, how and where to document. See Appendix D for the provider’s 
depression treatment and referral algorithm. The nursing and medical assistant staff who bring 




instructions for completing the screening tool using patient receptive dialogue, and from where 
to obtain screening forms.  
Process  
The following section describes the initial clinic work-flow process that was used during 
the implementation of this DNP project. The PHQ-9 tool was supplied digitally to the clinic by 
the student investigator. Nursing staff were responsible for printing and maintaining hard copies 
of the PHQ-9 screening tool in the clinic administrative office. As part of the patient rooming 
process, nursing staff, medical assistant, or technician gave a blank PHQ-9 form to the patient on 
a clipboard with a pen. Staff explained that the PHQ-9 screening was an evidence-based standard 
of care for patients with chronic HF and provided directions for how to complete the 
questionnaire. Staff were instructed to emphasize that patients were to answer questions based on 
symptoms over the previous two weeks. Patients completed the screening tool in a private exam 
room while waiting to be seen by a provider. If the patient had difficulty answering the 
questions, either nursing staff or the provider helped the patient complete the screening tool.  
During the clinic visit, the NP provider reviewed the completed PHQ-9 tool and 
document responses into the EMR which automatically generated a score. If the patient scored a 
ten or higher on the PHQ-9, the provider further assessed depressive symptoms during the clinic 
visit. After an assessment was completed, the provider discussed findings, treatment and follow-
up options with the patient and, together, they decided on a plan of care. The NP provider used 
the algorithm in Appendix D for patient referral and depression follow-up care to assist in 
clinical decision-making. Based on the algorithm, the LCSW was utilized to assist in patient 
follow-up and ensured that patients had the information needed to connect with referred services 
that best fit the patient’s geographic place of residence and financial ability. The NP provider 




assistance with finding services. If the patient scored less than ten on the PHQ-9, further 
assessment was at the NP’s discretion. If the NP determined there was no need for further 
depression treatment or follow-up, then the clinic would rescreen in three months, according to 
the clinic screening procedures.  
The NP documented the PHQ-9 score and related assessment and plan in the visit 
encounter EMR provider note by using an EPIC SmartPhrase which was a preconstructed 
template that inserted text and selectable text options into the provider note and included a link 
that automatically pulled PHQ-9 score data from within the patient chart. The PHQ-9 patient 
responses and score were documented in a designated section of the ambulatory care rooming 
documentation once patient responses had been obtained on the paper form. The NP was 
responsible for documenting PHQ-9 responses, patient assessment, and plan for follow-up based 
on the PHQ-9 score. Once the PHQ-9 responses were documented, the hard copy of the PHQ-9 
patient form was placed in the confidential recycle bin at the clinic. 
Should the patient respond with any frequency other than “not at all” to the final PHQ-9 
question that screens for suicidality, the NP provider further screened for suicidality risk using 
the four-question P4 tool that was built into the EMR. See Appendix C for P4 Suicidality 
Screener tool. The NP would then follow the facility policy for suicidality which entailed 
assessing if a higher level of care was indicated and followed the established clinic protocol for 
transfer to a higher level of care if necessary.  
PDSA Cycles 
Once education was completed, project implementation began. The project was 
structured using four PDSA cycles, each with two weeks of implementation and one week of 




PHQ-9 tool. To refine the workflow process, as discussed, the project began with two NP 
providers, one of which was designated the project champion.  
Data were collected from each PDSA cycle and then shared with clinic staff in real-time 
at the end of each cycle. Clinic staff were given an opportunity to provide feedback and 
suggestions on how to improve the process during each PDSA cycle. Any updates or changes in 
the process were communicated by the UNC DNP student and the project champion. The goal 
was to increase the number of patients who will be screened with each PDSA cycle. This would, 
in turn, increase the number of completed assessments, thus providing a greater number of 
patients the opportunity to be assessed for underlying depression and be further managed if 
indicated.  
Use of Stakeholder Feedback to Inform the PDSA Process 
Feedback throughout PDSA cycles mainly pertained to three elements: Determining who 
to screen, the screening process itself, and documentation and chart review. See Table 3 (p.79) 
for detailed PDSA cycles and stakeholder feedback used for revision.  
Determining Who to Screen. During the first PDSA cycle it was determined that 
telehealth patient encounters would be excluded from the initial project since those encounters 
had a different patient rooming process. In addition, due to the COVID-19 pandemic, work flow 
and processes for large scale implementation of telehealth was rapidly evolving. During the first 
PDSA cycle, it was also determined that all patients with HF that the two NPs cared for would be 
screened at least once every three months. Patients receiving care from the diuresis clinic often 
had multiple encounters in close succession with some patients scheduled in the clinic three days 
per week. Thus, for those with frequent encounters (e.g., the diuresis clinic) depression screening 





Screening Process. It was challenging for staff to adopt the screening process into their 
clinic routine. Some staff members acknowledged forgetfulness, indicating that at times 
screening was not done. Since nursing staff room patients for multiple providers throughout a 
typical clinic day, consistency with depression screening for two specific NP providers was 
challenging.  Over time, staff improved at remembering to screen. Changes were implemented to 
help improve compliance by encouraging the participating NP provider champions to ‘huddle’ 
with their rooming staff at the beginning of each shift to remind them to initiate PHQ-9 
screening. In addition, nursing staff moved copies of the PHQ-9 form into the exam room for 
easier access during the rooming process and to serve as a “cue to action.” Staff were also 
encouraged to link screening with other intake tasks associated with rooming (e.g., an initial 
diuresis clinic encounter).  
Some patients (n=4) were not screened because the NP deferred screening based on 
clinical judgement. For example, one patient was excluded from depression screening by the NP 
provider because of a significant psychiatric history, including dementia, and was already 
receiving care every three months by a psychiatric specialty clinic. In this case, the NP 
determined that the patient already had a robust mental health care plan in place. Providers used 
clinical judgement to exercise autonomy, including documentation of their decision making if 
depression screening for a specific patient encounter was deferred. As a result, clinical reasoning 
for deferred screening was added into the EMR SmartPhrase for documentation (consistent with 
recommendations from the literature).  
Documentation and Chart Review. Both NPs indicated that the PHQ-9 flowsheet (to 
document patient responses) and the EPIC SmartPhrase in the EMR (developed to streamline 




documentation, the NPs opted out of including an assessment and plan for patients with PHQ-9 
scores less than ten. However, the NPs identified that previously documented PHQ-9 scores were 
cumbersome. The NP providers were not easily able to determine, based on EMR 
documentation, if a patient had recently completed a PHQ-9 tool. Once this was identified in the 
first PDSA cycle, NPs began using the “sticky note” communication function in the EMR to 
communicate when the next PHQ-9 screen was due. However, in the second PDSA cycle, staff 
discovered that the “sticky note” information, unfortunately, was often deleted and was thus not 
a reliable way of communicating past screening efforts.  
During the third PDSA cycle, the clinic’s LCSW identified that patients were not being 
consistently referred to her for follow-up on elevated PHQ-9 scores. The NPs did not have a 
formal process, or mechanism to order, a consultation with the social worker. Therefore, the NP 
needed to communicate with the social worker by an EMR tag, EMR messaging, an in-basket 
tag, or verbally for any patient who would benefit from follow-up. During the project, the NP 
providers were encouraged to consider referral to the LCSW as a viable option for follow-up for 
patients with PHQ-9 scores greater than ten who were deemed to have depressive symptoms.   
Data Collection  
Data were collected from the EMR by the DNP student investigator and recorded into an 
Excel spreadsheet. Although inclusion criteria screening and data collection tools were designed 
for this project, ultimately data collection was streamlined for efficiency and accuracy with direct 
data entry into an Excel spreadsheet. The Excel spreadsheet was created by referring to the tools 
for data points. See Appendix E for the quantitative data collection form. The UNC SON 
compliance office granted the student investigator access to the EMR data. The EMRs accessed 




improvement project. Once the cases were identified from the provider patient list, the DNP 
student investigator extracted relevant data from the EMR. 
Baseline data were collected for two weeks prior to implementation of the new screening 
protocol. Quantitative data were collected by chart review and included patient demographics 
(age, sex), clinical factors (HF etiology, left ventricular ejection fraction status, NYHA class, 
stage of HF, past medical history of depression, past depression treatment history, PHQ-9 score), 
and the protocol compliance factors (number/percentage of patients with chronic HF seen by the 
participating provider, the number/percentage of PHQ-9 assessments completed, the 
number/percentage of PHQ-9 scores of ten or greater, the number/percentage of LCSW referrals 
placed, the number/percentage of pharmacy referrals placed, and the number/percentage of PHQ-
9 follow-up documented by the NP provider). Data were retrospectively collected for every day 
participating NP providers saw patients who met project criteria.   
All data collected were de-identified, ensuring patient privacy. Although the DNP student 
investigator temporarily had access to identifiable private information, the data needed for the 
project were abstracted in such a way that the information can no longer be connected to the 
identity of the subjects. This means that the abstracted data set did not include any direct 
identifiers (e.g., names, social security numbers) or indirect identifiers (e.g., codes that are linked 
to the participant’s identity). 
Each data collection form had a consecutive identification number on it (001, 002, 003, 
…) so that the patients’ data remained confidential. The coding numbers and the collected data 
were kept secure following the UNC-CH rules and regulations regarding data and information 




the study may be published in scientific research journals or presented at professional 
conference, but do not contain individually identifiable information. 
Data Storage 
All data were securely stored in a UNC password protected server behind a firewall. The 
UNC OneDrive through Office 365@ UNC system is a secure electronic storage database 
housed in a password protected firewall. This system allowed for the DNP student investigator 
and the faculty advisors (DNP committee) to collaborate during analysis.  
Data Analysis    
Quantitative data related to the patient characteristics and project outcomes were 
analyzed descriptively and reported as frequencies or percentages to evaluate the degree to which 
project outcomes were met. Data were analyzed to identify staff compliance in completing 
screenings and the rate of depression specific to this site’s target patient population. A screening 
goal of 50% was used. A follow-up documentation goal of 90% was used.  
Qualitative data related to process implementation were collected by the DNP student 
investigator from semi-structured discussions with staff and stakeholders during the study phase 
of each PDSA cycle. Staff, including the NP champion, who implemented the process were 
asked “What barriers have you encountered in the depression screening process?” and “What 
change would you implement to make this process more effective or efficient?” See Appendix F 
for a list of questions used to solicit staff discussion. Qualitative data were collected without 
identifying information (e.g., names, staff position) and recorded as field notes. Notes were 
analyzed on an iterative basis to inform revisions made as necessary during each PDSA cycle to 
support overall process feasibility, sustainability, and staff acceptability. Notes were maintained 
until the end of the project to allow for directed content analysis of the data to be used for 




At the project’s conclusion, a group interview was conducted with all staff who took part 
in the process. All staff participants were given the opportunity to provide private feedback via a 
written evaluation, verbal or telecommunication with the student investigator in the event that a 
participant was unable to attend the group interview, or did not communicate their feedback in 
the group setting. Inquiries were made specifically regarding the process’ impact on staff time 
and clinic flow. Staff were also asked if they found the practice change to be valuable to the 
patients that they serve and the quality of care in which they deliver. Eleven staff who 
participated in the project attended the group interview. One staff member, who was not in 
attendance, provided written feedback. See Appendix G for project conclusion questions and 
post-project written evaluation form.  
Communicating Results 
A summary of findings was emailed to staff participants at the end of each PDSA cycle. 
Project progress was visually shared with staff with a run chart and descriptive statistics 
(frequencies and percentages) of compliance of PHQ-9 completion that was posted in the staff 
breakroom. Charts were updated by the student investigator every one to two weeks during the 
project duration. Once the process was fully implemented and PDSA cycles were complete, the 
staff were invited to attend a post-implementation meeting to discuss the project outcomes. At 
the post-implementation meeting, project results were shared with staff participants and the 
group interview, as described above, was conducted. Based on project results, an executive 
summary, including recommendations for clinic next steps, was created and given to the NP 
project champion to share with the clinic administration and medical director of the HF program. 




Project Facilitators  
The proposed process lent itself to trialability as it did not create any permanent 
implications and, therefore, the process could be stopped or reversed without any negative effect 
to the clinic. In addition, because specialty appointment times for established patients were 
generally 30 minutes (versus a shorter time period for most primary care settings), time was 
viewed as a facilitator for routine depression screening in this cardiology specialty setting. The 
project setting, the UNC Heart Center at Meadowmont, is part of a mature and highly regarded 
healthcare system that possesses high quality social networks and community resource 
connections in addition to onsite social work services. This project had the support of strong 
opinion leaders from UNC-affiliated HF research and clinical practice, and cardiac psychology 
who were viewed to have influence over the attitudes and beliefs of their colleagues to promote 
implementation success (Damschroder et al., 2009). The project also had an identified NP 
champion from within the clinic who was willing and motivated to be a driving force throughout 
project implementation. Moreover, this project did not require equipment purchases or additional 
staff. For example, the healthcare system’s ambulatory EMR had a preexisting ability to 
document PHQ-9 patient responses which then provided automatic scoring. Scores were 
captured in data entry fields that were searchable and reportable, creating ease for data 
collection.  
Anticipated Project Barriers and Proposed Solutions 
This project sought to improve the quality of care provided to patients with HF by adding 
the additional steps of screening for and, if indicated, addressing depressive symptoms during a 
cardiology clinic visit. This could potentially have been seen by staff as time intensive or outside 
the scope of a cardiology specialty visit. A specific potential challenge for the cardiology NP 




biological mechanisms overlap. Moreover, when HF specialty services are provided, competing 
priorities may occur in real-time, which the provider ultimately needs to consider. For example, 
at times, initiating HF treatment for a change of status may be top priority placing depressive 
symptoms in the background to be addressed at a future follow-up visit, once the patient has 
stabilized.  
One remedy for this potential barrier was to provide education and a depression treatment 
and referral algorithm to the cardiology clinic NP providers. The clinic LCSW and psychologist 
were key stakeholders and assets to help further address and support patients who have a positive 
depression screening and assessment. The staff and NPs were educated on how to use 
preconstructed PHQ-9 documentation and an EMR Epic SmartPhrase was created for ease and 
efficiency of documenting the follow-up plan. Furthermore, clearly communicated expectations 
and responsibilities were presented with a simplistic process map that to help all staff and 
practitioners in better understanding their responsibilities.    
In addition, implementing routine depression screening among patients with HF may 
potentially identify patients who need referred to mental health resources; thus, the overall use of 
mental health services would be increased. One strategy to address this barrier was to build 
relationships to promote a network inside and outside of the organization to facilitate 
communication and collaboration (through a “warm handoff”) that would ultimately help project 
sustainability (Powell et al., 2015). Therefore, it was important to identify referral options to 
mental health community resources, and partner with or include complementary organizations in 
this project. The depression treatment and referral algorithm and use of the clinic’s social work 
resources was intended to facilitate viable referral options for mental health treatment within the 




Gaining staff buy-in, especially nursing and medical assistant staff, was identified as 
another potential barrier specific to this clinic. A strategy that was viewed as potentially helpful 
with engagement was to audit and provide feedback (Powell et al., 2015). Incorporating outcome 
data into quality reports generated from EMRs was viewed as a way of implementing an 
engagement strategy that had the potential to been associated with higher success among a QI 
project (Balasubramanian et al., 2018).  
Other engagement strategies included educational meetings for stakeholder groups that 
explained and demonstrated the importance of the project outcomes. This incorporated support 
and encouragement from the clinic’s psychologist and NPs who endorsed the project. These 
meetings were believed to be useful for building rapport and incorporating another engagement 
strategy, identifying champions, or individuals who will support, market, and drive the project 
purpose before, during, and after implementation (Damschroder et al., 2009). It was especially 
important to identify staff champions because this was a DNP student-led project. A 
spokesperson, directly from the staff who worked in the cardiology clinic and who would be 
directly affected by the new process, was needed to advocate for the change in practice and help 
other staff to assimilate. Obtaining project endorsement from the clinic’s HF program director 
was viewed as being highly beneficial to engage clinic staff.  
Unanticipated Barrier 
 An unanticipated barrier that occurred during the implementation period was a historic 
event, the COVID-19 global pandemic. In North Carolina, where this project was implemented, 
a statewide stay-at-home order was implemented on March 30, 2020 and continued through May 
8, 2020. Due to escalating pandemic severity and state restrictions, in-person clinical was 




2020. Beginning on March 23, 2020, 80% of clinic visits were changed to a virtual telehealth 
platform. The clinic observed an 80% decrease in patient volumes in March, 2020.  
The COVID-19 pandemic response initially placed physical limitations on this project. 
Therefore, the project proposal was discussed with faculty advisors to identify revisions or a 
contingency plan to make the project work within the pandemic limitations. The project proposal 
was approved on April 4, 2020 and the UNC Office of Human Research Ethics determined that 
the project did not constitute human subject research and, therefore, did not require IRB approval 
on April 29, 2020. Project implementation was postponed by approximately one month. Initial 
project education and ramp-up was done remotely via Zoom on May 28, 2020 rather than in-
person as originally planned.  
Beginning in June, in-person clinic visits resumed. The majority of patients were seen 
face-to-face in the clinic. The first two weeks of the project were monitored remotely by the 
student investigator. The clinic allowed students to return to in-person clinical on June 22, 2020. 
By mid-June, the NP project participants’ patient volumes were similar to pre-COVID patient 
volumes. Several nursing and ancillary staff were initially furloughed from the clinic in March, 
2020 but returned in June, 2020. The original project proposal included inviting other providers 
to participate in the process improvement in an effort to implement depression screening for all 
patients with chronic HF who were cared for at the clinic. However, due to the pandemic, the 
project committee decided to scale back initial implementation and limit to the two NPs who 
were already vested in the project. During the entire project implementation, visitors were not 
allowed in the clinic unless it was medically necessary to accompany a patient. See Appendix I 





One essential key to the sustainability of this project was the EMR infrastructure that had 
the PHQ-9 screening tool already built into the ambulatory care charting system. This facilitated 
screening, automatically scores responses, and storage of data input related to the PHQ-9 in a 
quarriable way that allowed for easy data collection. The clinical use of the Substance Abuse and 
Mental Health Services Administration (SAMHSA) treatment directory 
(https://www.samhsa.gov) also ensured that clinic staff could locate current community referral 
information for pharmacologic and nonpharmacologic depression management. Having a full-
time LCSW at the clinic who can follow-up with patients who have elevated PHQ-9 scores also 
helped the project’s sustainability.  
A potential barrier to sustainability is long-term staff fidelity to the process. Clinic 
champions need to continue to support and encourage staff to maintain the process. Increasing 
greater universality of clinic practice by eventually screening all cardiology clinic patients will 
help fidelity to screening and follow-up. It is easier to hold staff accountable to a practice change 
if it is a process that is intended for every patient, at every visit. Thus, opportunity exists for 
future projects to show the importance of depression screening for all patients with 
cardiovascular conditions.  
Budget 
This project had minimal associated direct costs that included paper and printing supplies 
for patient screening tools, snacks for staff provided on a weekly basis, and lunch provided to 
staff at the beginning and end of the project. Estimated direct cost was $450. The largest indirect 
cost was staff and provider time required for initial education, project implementation, and 
progress discussions after each PDSA cycle. Anticipated resources needed to continue the 




screening tool and the provider time to address the assessment during the clinic visit. Clinic 
LCSW and pharmacy services will also be a valuable resource moving forward to assist the 
providers with patient follow-up for elevated PHQ-9 scores.  
69 
CHAPTER 4: RESULTS 
The project desired outcomes were to create a sustainable process for the cardiology 
clinic to screen patients with chronic HF for depression, to identify patients who had an elevated 
depression screening score, and for providers to initiate an evidence-based treatment algorithm 
for those patients. Compliance was measured by the frequency and percentage at which 
screening assessments were completed. The impact of screening (clinical outcome) was 
measured by the percentage at which providers documented an assessment and plan for patients 
who had an elevated depression screening score and number of patients for which the provider 
initiated or referred for depression treatment using the algorithm.  
Baseline Clinic Data 
Baseline clinic data were collected from May 25, 2020 to June 5, 2020. During this two-
week period, the two NP providers identified to pilot the project had 69 patient encounters with 
41 of those patient encounters that met project criteria for depression screening. Of those 41 
patient encounters, none of the patients had documentation of depression screening (by the PHQ-
9). These data confirmed that there was no clear process for depression screening during routine 
clinic visits for patients with chronic HF.  
Screening Compliance  
Compliance was measured by the frequency/percentage at which screening assessments 
were completed and the frequency/percentage at which providers documented an assessment and 




follow-up documentation goal of 90% was used. These goals were based on comparable 
depression screening goals in the literature. 
Depression screening using the PHQ-9 tool was completed with patients with chronic HF 
seen by two NPs for eleven weeks (from June 8, 2020 until August 21, 2020). Screening 
percentages for each PDSA cycle were 40%, 77%, 72%, and 69%, respectively. Over the 11-
week implementation period, out of a total of 429 patient encounters, there were 240 patient 
encounters (56%) that met criteria to be screened. Of those eligible, 151 were screened over the 
course of the project, yielding an overall screening compliance rate of 63% (exceeding the 
project goal of 50%). There were 192 unique patients eligible for screening.  
Sample Characteristics of Eligible Patients 
The mean age of the 192 unique patients eligible for screening was 61.7 years (SD 13.8) 
with an age range from 20 to 97 years.  Forty-three percent (n=82) were female. About one in 
four patients had a history of depression (26%; n=49), while 13.5% (n=26) had a history of other 
neurological or psychiatric diagnosis. Current (or history of) antidepressant or psychotropic 
medication use was documented in 34% (n=66) of the patients.  
Patient clinical HF variables recorded included type of HF diagnosis, HF etiology, left 
ventricular ejection fraction (LVEF), and NYHA Class.  Documented diagnoses consisted of HF 
with reduced ejection fraction (HFrEF) 66% (n=127), HF with preserved ejection fraction 
(HFpEF) 24% (n=47), and combined HF 7% (n=13). Type of HF diagnosis was not recorded for 
five patients. About one in five patients had an ischemic etiology to their HF (21.4%; n=41) with 
142 (74%) patients having a nonischemic etiology. Etiology was not recorded for seven patients. 
The mean LVEF recorded in the medical record of the patients was 37.5% (SD 16.42%). A little 
over half of the patients (54.7%; n = 105) had an LVEF of less than or equal to 40%, while 




preserved LVEF of 50% or greater. The NYHA functional class for the patients consisted of 
nineteen patients with an NYHA Class I (9.9%) meaning they had no symptoms of HF on the 
day of the visit.  Whereas about one in four (24.5%; n=47) were classified as NYHA Class II, 
meaning they were slightly limited by their HF symptoms.  Notably, 26 patients (13.5%) were 
classified as being in NYHA Class III (markedly limited in activities by their HF symptoms), 
while no patients were classified as having symptoms at rest (NYHA Class IV). It is important to 
note that in a little over half of the 192 eligible patients (52.1%; n=100) did not have their 
NYHA Class documented in the medical record on the day of screening. Refer to Table 3 for a 
summary of the sociodemographic and clinical characteristics of the 192 eligible patients. 
Table 3: Characteristics of eligible patients 
Variable n (percentage) Mean (SD) 
Age in Years 
 
61.68 (13.80) 
Female  82 (43%) 
 
History of Depression 49 (26%) 
 










     HFrEF 127 (66%) 
 
     HFpEF 47 (24%) 
 
     Combined HF 13 (7%) 
 




     Nonischemic 142 (74%) 
 
     Ischemic 41 (21.4%) 
 





     < 40% 105 (54.7%) 
 
     41-49% 27 (14.1%) 
 




     Class I 19 (9.9%) 
 
     Class II 47 (24.5%) 
 
     Class III 26 (13.5%) 
 
     Class IV 0 (0%) 
 






Characteristics of Ineligible Patients 
There were 96 unique patients deemed ineligible for screening according to the project 
inclusion criteria. Notably, 39% of ineligible patient encounters were patients being seen for a 
different cardiology service (electrophysiology subspecialty), 35% had already been screened 
within the past three months, 17.4% were telehealth visits, 4.8% were deferred by the provider 
for various reasons, and 1.6% were medically unstable.  During the project implementation 
period, two patients with electrophysiology subspecialty encounters were screened using the 
PHQ-9. These patients did not meet project inclusion criteria and were excluded from data 
analysis.  
Depression Screening Yield 
Over the 11-week project implementation period, there were 20 unique patients (13.2%) 
who had an elevated depression score (PHQ-9 score 10 or greater). Based on further assessment, 
providers determined that 80% (n=16) of elevated depression scores were due to depressive 
symptoms, while 20% (n=4) of elevated depression scores were attributed to HF symptoms. One 
patient who did not meet project inclusion criteria was screened and had an elevated PHQ-9 
score. These data were excluded from analysis. Notably, of those who had elevated PHQ-9 
scores, 100% (n=20) had a HFrEF diagnosis, 90% (n=18) had a nonischemic HF etiology, and 
80% (n=16) had a history of either a mental health diagnosis or psychotropic medication use. 





Table 4: PDSA cycles 
PDSA 
Cycle  
Dates Goal % of 
Patients 
Assessed   
















50% 40% 10% 100% - No screening for telehealth 
visits.  
- Patients at diuresis clinic do 
not need to be screened at 
every appointment. Patients 
should be screened by the 
clinic every 3 months. 
Provider to place due date for 
next screening in chart ‘sticky 
note.’ 
- Providers to connect with 
rooming staff at the beginning 
of each shift to remind staff to 
initiate PHQ-9.  
2 6/29-7/16 
 
50% 77% 9% 100% - Link screening with initial 
diuresis visit tasks.  
- Providers do not need to 
address PHQ-9 in assessment 
and plan if score is less than 
10.  
- Keep stack of PHQ-9 forms 
in the exam room.  
- Providers to connect with 
rooming staff at the beginning 




50% 72% 14.5% 100% - Provider to consul social 
work via EMR 
tag/message/in-basket for any 
patient who would benefit 
form PHQ-9 follow-up.  
- Provider to consider social 
work follow-up for all patients 
who score PHQ-9 greater than 
10.  
- Provider to document 
clinical reasoning for deferred 




50% 69% 22.7% 100% - Results sharing and staff 
participant discussion at the 
conclusion of PDSA cycle.  
- Provider to initiate 
psychiatry referral within 24 
hours of patient encounter 





Impact of Screening  
The impact of depression screening (the clinical outcome) was measured by the 
number/percentage of patients for which the provider initiated or referred for depression 
treatment using the algorithm. As noted, a project goal was to give NP providers an evidence-
based treatment algorithm to guide treatment initiation for patients identified with depressive 
symptoms. Thus, the NPs implementing the project were asked to document an assessment and 
plan for every patient encounter with a PHQ-9 score of ten or greater. Results revealed that NPs 
documented an assessment and plan for 100% of encounters that met criteria, exceeding the 
project goal of 90% documentation compliance.   
Specifically, NPs initiated and documented an intervention for all 16 patients who had a 
PHQ-9 score of 10 or greater due to depressive symptoms. Based on clinical assessment of 
elevated depression symptoms, NPs initiated the following interventions: primary, psychiatric, or 
psychological care referral (11); LCSW referral (9); financial assistance referral (4), medication 
initiation or titration of antidepressant therapy (5); cardiac rehab referral (2); and a prescription 
for increased exercise (2).  
Post Implementation Staff Feedback 
Qualitative data from staff during at the project’s conclusion revealed four key themes 
relating to feedback on the quality of patient care provided, clinic screening process, 
documentation and chart review, and patient follow-up.  
Quality of Care Provided 
Data from semi-structured interviews with staff revealed overwhelming support from 
participating nursing staff, two NPs participating in the project, the LCSW, and the clinical 
psychologist to continue depression screening.  Interviewees advocated for broad scale 




as all patients seen in the cardiology clinic. Staff saw depression screening as a vehicle for 
providing a holistic approach to care that added value and improving the quality of care 
delivered to clinic patients. In fact, staff noted how the screening tool was a conversation starter 
to assess and identify medical and psychosocial needs for patients that otherwise may not have 
been discovered. For example, by administering the PHQ-9 and providing further assessment, 
staff were able to identify homelessness in one patient and untreated sleep apnea in another 
patient and were able to facilitate appropriate services.  
Clinic Screening Process  
Time Commitment and Clinic Flow 
Based on feedback from those interviewed, depression screening was not viewed as time 
consuming and did not impede clinic flow. The nursing staff estimated that it took less than one 
minute to explain and distribute or administer the PHQ-9 paper form. It took NPs an estimated 
less than one minute to score and document the PHQ-9 patient provided responses. Assessment 
and planning for patients with elevated PHQ-9 scores took NPs an estimated five and ten 
minutes to complete. These time commitments were in line with staff and provider expectations 
and were not viewed as burdensome to patients or staff. 
Screening Compliance 
Since the nursing staff room patients for multiple providers throughout a typical clinic 
day, consistency with depression screening for two specific NP providers was challenging.  The 
nursing staff suggested that broadscale implementation within the clinic (i.e., every patient; 
every time – unless contraindicated) would enhance compliance by incorporating a habitual 




Documentation and Chart Review 
Both NPs indicated that the PHQ-9 flowsheet (to document patient responses) and the 
EPIC SmartPhrase in the EMR (developed to streamline documentation of PHQ-9 assessment 
and plan) were easy to use. The NPs also identified a need for a more efficient way for staff to 
view PHQ-9 score flowsheets (all scores and dates of screening) to know if a particular patient 
was due for screening. Moreover, there was a need to easily view in the EMR how, if ever, 
scores change over time.  
Patient Follow-Up 
The staff discussed the importance of follow-up for patients who had an elevated PHQ-9 
score and were subsequently deemed to have depressive symptoms by the NP. The nursing staff 
were also concerned with those patients with ‘borderline’ scores, who may not have met the 
PHQ-9 cut off of ten, but still warranted symptom monitoring. Reassurance was given to staff 
related to the sensitivity of the PHQ-9 and the need to screen each patient at least every three 
months. 
Although the LCSW at the site was willing to follow patients with who scored above the 
PHQ-9 cutoff, patients were not being consistently referred to the LCSW. This may have been 
because the NPs did not have a formal process, or mechanism to order, a consultation with the 
social worker. Therefore, the NP needed to communicate with the LCSW by an EMR tag, EMR 
messaging, an in-basket tag, or verbally for any patient who would benefit from follow-up. A 
streamlined process for LCSW referral was needed. This project algorithm did not indicate that 
every patient with an elevated PHQ-9 should be referred to social work but that the referral was 
an option at the discretion of the NP. An expectation of when to consult social work was also 




The NPs reiterated the importance of having a plan for those who disclosed suicidal 
ideations.  Although encounters with patients that have suicidal ideations are rare, the situation is 
high-risk and time-sensitive. After one such situation arose during the third PDSA cycle, a more 
deliberate educational effort was made to remind NPs of the need for psychiatry referral within 
24 hours of patient encounter for those with suicidal ideations.  
Recommendations for Clinic Next-Steps 
At the project conclusion, the executive summary and project recommendations were 
given to the NP project champion to share with clinic administration and the director of HF and 
heart transplant management. The project committee recommended to continue the current 
screening process with the two original NP project champions. Recommendations were made for 
the clinic to formally identify a project lead, an NP champion, and nurse champion to maintain 
momentum and facilitate next steps.  
Recommendations for next steps include reviewing the current process and determining a 
roll-out of staff-suggested changes. For example, process review could include evaluating the 
best time to administer the screening, determining if any changes are needed for who would 
document initial screening score, and which providers would be added to the screening process 
in the next phase of launching depression screening in the clinic. A recommendation was made 
for the designated team to consider inviting another graduate nursing or health affairs student to 
enhance future plans for more full-scale depression screening.  
Additionally, recommendations were made to add a case study approach to train nursing 
staff and providers on implementation of screening and referral processes. This would enhance 
staff education and relay important lessons learned during the initial project specific to both 
common and rare, high-risk patient presentations. Specific case studies may include a patient 




elevated PHQ-9 score who screens positive and deemed by provider have elevated depressive 
symptoms, and a patient who screens positive for suicidal ideation. 
To continue to provide staff with meaningful data, recommendations were also made for 
the clinic to identify a champion to specifically provide compliance feedback to the team and 
clinic at large (e.g., number/percentage of positive screens, number/percentage of those who 
received interventions). The clinic could also consider implementing a regular audit system to 
ensure that follow-up is documented for those who screen positive. 
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CHAPTER 5: DISCUSSION 
The overarching goal of this project was to create a sustainable process for an outpatient 
cardiology clinic staff to screen patients with chronic HF for depression. Overall, this goal was 
achieved. We met the metric goals set for screening compliance and follow-up documentation. 
Moreover, we provided the clinic with suggestions for how to make the established screening 
and referral process sustainable.  
COVID-19 Pandemic  
While the full extent is unknown, it is clear the COVID-19 pandemic impacted this 
project. The pandemic required initial staff education to be conducted virtually.  Moreover, the 
first two weeks of project implementation did not have onsite support from the student 
investigator. Therefore, it is plausible that COVID-19 effected initial rates of compliance, staff 
engagement, and process clarity.  It is also plausible that patients were experiencing increased 
depressive symptoms manifested during the COVID-19 global pandemic. Stay at home orders, 
social isolation, fears of COVID-19 contracting, and general uncertainty were potential stressors 
for patients and their caregivers during the project implementation period. Furthermore, these 
same stressors undoubtably impacted the staff. Interestingly, staff commented that, more than 
ever, it was important to assess patients’ mental health during the pandemic. Thus, the pandemic 
may in fact have led to higher staff engagement.   
This project provided patients an additional service during a global pandemic that may 
have ultimately changed their clinic experience. Clinical staff offered patients the opportunity to 




psychologically. This gave many patients the permission to express themselves and start a 
conversation with their provider about their mental health at a time when they may have needed 
a holistic approach to health care delivery, more than ever.  
Screening Compliance  
This project established an overall screening compliance of 61.9%, notably lower than 
the 75.9 to 93% range of outpatient screening compliance as cited in the literature (Aleem et al., 
2015; Peters et al., 2020; Russomagno & Waldrop, 2019). However, at baseline there was no 
systematic process in place for routine depression screening at the site.  In the 11-week 
implementation period, attaining depression screening in nearly two out of three patients with 
heart failure is laudable.  Furthermore, as noted, the project was implemented during the 
COVID-19 pandemic.  
Depression Screening Yield 
As discussed, our screening yielded 21 unique patients (13.7%) who had elevated 
depression scores (PHQ-9 score > 10), comparable to the positive yield from screening with the 
PHQ-9 (with a cutoff of 10 or higher) from the literature which consistently reports 
approximately one in five (20%) adults with HF.  We were able to identify nearly one in every 
seven unique patients with HF over the 11-week implementation period.  Notably, it is plausible 
that some patients with elevated depression symptoms were missed because clinically unstable 
patients and those who had virtual (telehealth) visits were excluded.  Likewise, it is unknown 
how including patients with HF who were receiving care through telehealth would have changed 
the yield obtained.  
Based on further assessment, NP providers determined that 81% (n=17) of those with 
elevated PHQ-9 scores (10 or higher) were due to depressive symptoms.  Comparison of this 




when clinical confirmation of depression is varied, including who makes the determination (e.g., 
provider, psychologist, LCSW) as dictated by workflow.  
Impact of Screening  
 In our project, impact of screening was defined as initiation of the treatment plan for 
those identified as having increased depressive symptoms. As discussed, we were successful in 
documenting an assessment and treatment plan for all 21 unique patients with elevated PHQ-9 
scores, thereby meeting our project goal of following the evidence-based algorithm adopted for 
the setting. Comparing impact of screening with studies from the literature is challenging as very 
few studies reported these data.  However, our results were markedly better than those of 
McIntosh (2017) who found in a post implementation sample chart review that nursing 
documentation of depression screening improved from baseline while the provider 
acknowledgement of screening results was not clearly documented. Another study addressed the 
impact of screening as they reported a clinically significant increase in referral rates for mothers 
from a baseline of 66% to 79% after implementing a standardized depression screening and 
referral algorithm (Russomagno & Waldrop, 2019).  
Treatment varied for the 17 unique patients that the NP providers determined to have 
elevated depressive symptoms, aligning with best practice for shared-decision making that 
incorporates patient preferences into treatment plans. The NPs initiated treatment and/or referrals 
consistent with evidence-based options in the literature for patients with HF, including 
psychiatric/psychotherapy referrals (8); antidepressant medication initiation or titration (5); and 
exercise therapy (4). Four patients had a plan that combined more than one treatment modality 
(also consistent with evidence-based recommendations in the literature). Notably, some 




social determinants of health (e.g., financial assistance) which was evidence of a holistic care 
approach within the clinic.  
Themes of Staff Participant Feedback  
Staff showed overwhelming support of screening their patients with HF for depression. 
Moreover, staff verbalized depression screening improved the quality of care they provided their 
patients and saw value in broad scale implementation for all cardiac patients seen in the clinic. 
By encouraging communication, screening yielded positive unintentional consequences. 
Additionally, staff feedback echoed key elements of implementing depression screening found 
the literature including optimizing EMR utilization and ensuring patient follow-up (Aleem et al., 
2015; Berge et al., 2019; Peters et al., 2020; Russomagno & Waldrop, 2019; Smolderen et al., 
2011; Waldrop et al., 2018).  
Implications for Future Projects and Practice  
EMR Utilization  
As evidenced by our project, it is vitally important to build EMR infrastructure that 
incorporates documentation templates for evidence-based screening tools. This includes 
automatic scoring and branching of tools calculated by documented patient responses. This 
infrastructure could include EMR programming that automatically cascades from the PHQ-2 to 
PHQ-9 if the PHQ-2 cutoff score is met and that prompts a suicide severity screening (e.g., P4) if 
a positive suicidality response is documented. Additionally, efficiency and compliance may 
improve when scores are able to be pulled for reporting purposes and automatically imported 
into provider notes. Eliminating paper tools and directly documenting patient responses into the 
EMR either by staff or patient self-report (e.g., via iPad, cell phone application, or electronic 
kiosk) could also benefit process compliance and efficiency.  These solutions involving EMR 





As discussed, our findings reinforce the need for an adequate follow-up process for those 
with a positive depression screen as indicated in the literature (Berge et al., 2019; Peters et al., 
2020; Russomagno & Waldrop, 2019; Waldrop et al., 2018). Other clinician roles (e.g., LCSWs, 
psychologists) could be better integrated into the treatment plan and/or patient referral process. 
For this project, the LCSW was engaged and willing to provide follow-up for patients who had 
elevated PHQ-9 scores deemed to be depressed by the NP. An opportunity exists to establish a 
more formal structure for referring patients to the LCSW and to develop a process for when and 
how often to follow-up with patients. For example, there was no consistency in how or if the 
LCSW was being notified of elevated PHQ-9 scores. Therefore, creating an EMR pathway for 
the provider to order a consultation specifically with the LCSW in the cardiology clinic was 
needed to ensure follow-up. One solution identified by Peters and colleagues (2020) was to 
establish a protocol with follow-up at 1-week, 1-month, and 3-month intervals.  
Ultimately mental health providers within the community, such as providers who 
prescribe antidepressant therapy and medication management for patients served at this clinic, 
are project stakeholders that may see potential impact from this project and should be considered 
in long-term planning.  Establishing a relationship with the psychiatric service where warm 
hand-offs can take place would be potentially beneficial to patient care in future projects that 
implement depression screening.   
Depression Screening for Patients with HF  
Depression screening protocols for patients with HF are underrepresented in the 
literature.  More studies are needed that evaluate the effectiveness of pharmacotherapy in the HF 




options and the effects of combining treatments (e.g., CBT and SSRI therapy vs CBT alone) in 
the HF population.  
An emerging intervention for depression in patients with HF is collaborative care. These 
programs use clinical care managers to assess and longitudinally monitor patients and coordinate 
delivery of psychosocial interventions (Zambrano et al., 2020). For example, in an effort to find 
treatment options that improve patient outcomes, the Hopeful Heart Trial is currently comparing 
the effects of “blended” collaborative care, traditional collaborative care, and usual medical care 
in treating patients with comorbid depression and HF with reduced ejection fraction (Herbeck 
Belnap, et al., 2019).  
Finally, continued efforts are needed to incorporate use of standardized evidence-based 
culturally relevant verbal and written education for patients with HF who have elevated PHQ-9 
scores deemed to be depressed, including a list of local resources (adapted to the specific 
geographical location).  While each setting could develop their own educational products, 
standardized education that could be personalized to the patient and setting are needed.  
Recommendations for Screening Frequency 
Guideline recommendations for the best time interval between visits for routine 
depression screening are needed. Generally, the most common interval seen in practice is 
annually. However, recommendations based on research or expert consensus are needed to 
provide guidance to clinicians who care for patients with chronic conditions such as HF, who are 
at higher risk for depression than the general patient population. Recommendations should 
address whether patients at higher risk for depression (which would be specified) should be 
screened more frequently than the general population. Furthermore, recommendations are needed 
to address intervals for screening in both patients with and without history of elevated scores.  




are needed to determine if repetitive use of the same tool is clinically useful to track severity of 
depressive symptoms and effectiveness of treatment. Once recommendations are established, 
process implementation solutions are needed to identify when patients are due for depression 
screening. For example, Aleem and colleagues (2015) used a colored sheet method to indicate if 
a patient had a documented PHQ-9 score within the set timeframe. Ultimately, it will be helpful 
for clinicians to utilize a workflow established within the EMR to determine when screening is 
due.  
Future Screening Efforts 
Despite implementation efforts and notable improvements to screening, results from our 
project, consistent with those in the literature, demonstrated that roughly one in four patients are 
not routinely screened for depression. Continued process improvement efforts are needed to 
increase screening compliance. Efforts should also target the subset of patients with HF who are 
at highest risk for depression (i.e., patients who are younger than 60 years of age, women, never 
married, or with low socioeconomic status) (Chobufo et al., 2020; Smolderen et al, 2011).  In 
addition, processes for determining whether patients who are traditionally excluded from 
depression screening in the outpatient setting are experiencing depression symptoms, should be 
considered.  For example, if a patient is excluded from screening due to being acutely ill and in 
need of hospitalization, transitions of care into the hospital setting should include communication 
to continuing care providers to initiate depression screening once the patient stabilizes. 
Clinical Confirmation of Depressive Symptoms  
While screening tools are clinically useful, they are only intended to screen patients, not 
for confirmation of a clinical diagnosis. Clinical confirmation is essential to provide discernment 
of whether heightened scores reflect major depression, situational/acute depression, or another 




elevated PHQ-9 score is necessary. Although a clinical interview was completed by a NP and 
clinical confirmation was described for this project, the process of clinical confirmation is not 
routinely discussed in the literature. The literature reviewed reported depression among the 
sample populations based on screening tool scores. However, future reports need to include 
depression screening scores in addition to the clinical confirmation of those scores. This is 
especially important for the HF population to address the gap noted in the literature.   
Screening for Suicidality 
 Endorsement of suicidality during depression screening, although a relatively rare 
occurrence, presents a potentially high-risk situation. Thus, it is imperative to include a process 
to address and intervene for a suicidal patient when initiating depression screening. Moreover, 
this process needs to be clearly defined and communicated to participating staff so that they may 
provide the safest patient care. To reinforce process expectations, providers could potentially 
learn by case-based study approaches that review the required risk assessment (e.g., P4 
Suicidality Screener), documentation, and steps for follow-up if a patient endorses suicidality. 
Furthermore, providers need readily accessible facility policies for emergency transfer, patient 
education, and necessary psychiatric patient referrals when this rare, but high-risk, situation 
presents itself. 
Telehealth Capabilities 
While we excluded telehealth patient encounters, a growing need exists to adapt best 
practice processes for patients who obtain healthcare virtually. The current global pandemic has 
reinforced the need to have processes and infrastructure in place to screen patients for depression 
using telehealth.  Thus, projects are needed that build infrastructure for depression screening and 
referral systems for telehealth.  Treatments options (e.g., psychotherapy) with telehealth 




transportation, and pandemic related social distancing recommendations.  As noted by Koehler 
and colleagues (2020) telemedical care delivered via daily telemonitoring, 24/7 medical support, 
and monthly clinician interaction, have been shown to improve depressive symptoms and results 
in improved QOL in patients with HF and moderate depression. In the midst of COVID-19 and 
beyond, it is plausible that the broadscale use of telemonitoring as an enhancement to usual care 
may improve depression symptoms and QOL.  However more research is needed to test this 
hypothesis.  
Limitations 
There were some limitations to this process improvement project. Consistent with a 
PDSA process improvement project, a limitation of the project was that implementation was 
done on a relatively small scale at one site with two NP providers.  In addition, compliance 
measured over a relatively short duration of 11 weeks. However, it is important to note that there 
was no pre-existing process in place for depression screening at this large cardiology practice.   
In addition, it is unknown whether the success would be transferable to other clinic settings with 
less resources available.  For example, our project had a LCSW, a clinical psychologist, and 
pharmacy support available onsite.  All clinics, especially those outside of an academic setting 
may not have these resources.  A third limitation of the project was that we did not record the 
percentage of patients that opted out of screening; therefore, we are unable to objectively 
describe patient acceptability of screening. A final limitation was that we were unable to 
incorporate the EMR development team into the planning and implementation of the project.  
Thus, we utilized preexisting EMR structure and functions, including negating any opportunity 
to improve existing processes. However, it was not feasible to include the EMR development 
team in our planning due to priority shifting during the COVID pandemic. Opportunities remain 





 Despite the limitations noted above, we were able to implement the project, meeting 
goals, in the middle of a pandemic.  We implemented depression screening using a one-step 
validated and widely-used screening tool that staff found to be acceptable in a setting where 
systematic screening was not occurring. Our results also demonstrate success in providing 
holistic quality care to patients at a higher risk for depression as compared to the general 
population.  Lastly, this project adds to the small body of literature that shows how depression 
screening can be successfully implemented in a specialty clinic.  
Conclusion 
Routine depression screening is an important part of the holistic approach to HF care. 
Assessing and addressing comorbid depression in patients with chronic HF is recommended by 
clinical practice guidelines. Results from this process improvement project found that depression 
screening was well-received among staff. We demonstrated how a screening protocol and an 
accompanying treatment algorithm can be successfully implemented into an outpatient 
cardiology clinic. Key elements to the successful screening implementation included a 
standardized screening protocol, a clinical support algorithm for treatment/referral, an optimized 
EMR infrastructure that supported the depression screening tool used, and a system in place for 
follow-up of patients deemed to have significant depressive symptoms. Stakeholder engagement 
prompted PDSA cycle feedback that informed iterative changes made to the process over the 
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APPENDIX B: PHQ-9 SCREENING TOOL 
 







APPENDIX C: P4 SUICIDALITY SCREENER 
 

















Student Investigator: Elizabeth Wilhelm 
 









Date of Clinic Visit: ____/____ /____    Subject ID________ 
Date of Chart Audit: ____/____ /____ 





Inclusion Criteria:   
Heart failure diagnosis   Yes  No → Exclude       
(stop) 
 
Established patient    Yes  No → Exclude       
(stop) 
 
Exclusion Criteria:    
Non-native English speaker    Yes→ Exclude    (stop)   No 
 

















If the patient qualifies: 
Patient Information (from the medical record): 
Variable Answer Comments 
Age in years 
   
Sex 
           Male   Yes    No  
           Female   Yes    No  
          Other   Yes    No  
Heart Failure Etiology 
          Coronary Heart Disease   Yes    No  
          Hypertension    Yes    No  
          Idiopathic    Yes    No  
          Other   Yes    No Specify: 
Type of Heart Failure 
          Reduced LVEF   Yes    No LVEF: ___% Date: ___ 
          Preserved LVEF   Yes    No LVEF: ___% Date: ___ 
          Other    Yes    No Specify: 
NYHA Class (day of visit)   
Stage of Heart Failure (day of visit)   
Past medical history of depression 
documented in problem list or note   Yes   No  Specify: 
Past treatment for depression treatment 
documented in the problem list or note 
           Antidepressant  Yes    No Specify: 
           Cognitive behavioral therapy  Yes    No Specify: 







Screening Outcome Information (from the medical record): 
Variable Answer Comments 
Completed PHQ-9  Yes   No  Specify: 
PHQ-9 Score   
PHQ-9 Score ≥10  Yes    No Specify:  
New diagnosis of depression documented   Yes    No Specify:  
PHQ-9 follow-up documented by provider  Yes    No Specify:  
Social work referral  Yes    No Specify:  


















APPENDIX F: QUESTIONS TO GUIDE STAFF DISCUSSION 
1. How familiar are you with your clinic’s depression screening process?  
2. How likely are you to use the depression screening process? 
3. How likely are you to have enough time to screen for depression? 
4. How confident are you in managing depression?  
5. How comfortable are you with prescribing antidepressants? 
6. Do you want more information on assessment and management of depression? 
7. How do you prefer to learn? 
8. What barriers have you encountered in the depression screening process? 
9. What change would you implement to make this process more effective or efficient? 
Questions to Guide Final Staff Discussion 
1. How likely are you to sustain depression screening in your practice? 
2. What are lingering challenges to implementing depression screening? 





APPENDIX G: PROJECT CONCLUSION QUESTIONS AND POST-PROJECT 






APPENDIX H: EXECUTIVE SUMMARY 
Assess and Address: Screening and Management for Depression 
in Patients with Chronic Heart Failure 
 
UNC School of Nursing DNP Project 
Elizabeth Wilhelm 
 
Executive Summary: October 21, 2020 
 
Project goal #1: To create a sustainable process for an outpatient cardiology clinic staff to screen patients 
with chronic heart failure (HF) for depression.  A screening goal of 50% was used.  
 
 
• Results Depression screening using the PHQ-9 tool was completed with pts with chronic HF seen 
by nurse practitioners, Sarah Waters and Emily Baker, between June 8th and August 21st 2020.  
▪ Patients who met criteria for screening: 240 
▪ Total pts screened: 153 





Project goal #2: To identify the rate of patients with elevated depressive symptoms among the clinic’s 
HF population. 
 
o Results  
▪ Number of unique pts with elevated depression score (PHQ-9 score 10 or greater): 21 
▪ Percentage of pts screened with an elevated depression score: 13.7% 
▪ 2/3 of elevated depression scores were due to depressive symptoms based on provider 




Project goal #3: To provide an evidence-based treatment algorithm to guide providers in treatment 
initiation for patients identified with depressive symptoms.  The goal for provider documentation of an 
assessment and plan for patients with an elevated depression screening score was 90%. 
• Results 
o Providers were given an algorithm and EPIC Smartphrase to document an assessment and 
plan for patients who had an elevated depression score (PHQ-9 score 10 or greater).  
o Documentation compliance: 100%  
o Interventions documented included: referral to psychiatry, clinical psychology, clinical 
social work, primary care, or cardiac rehab; medication initiation/adjustment, financial 
assistance; encouraged exercise. (*Note: some patients received more than one of these 
interventions) 
Summary of Debriefing Session with Staff: 
• Overwhelming support from participating nursing staff, NP providers, social work, and clinical 
psychologist to continue depression screening and to expand screening for broad scale 
implementation. 
• Value seen in how depression screening provides a more holistic approach to care and improves 
quality of care.  
• The screening tool served as a vehicle for conversation for uncovering unmet medical and 
psychosocial needs that otherwise may not have been shared.  
• Screening is not time consuming and does not impede clinic flow.  Assessment and plan for 
patients with an elevated score took approximately 5-10 minutes of provider time.  
• Need to ensure follow-up for patients who have elevated scores and are deemed depressed by 
provider (including those who are borderline). 
• Clinical Social Work (Lindsay Mosteller) willing to follow patients with elevated PHQ-9 scores 
• Providers reiterated the importance of having a plan for those who disclose suicidal ideations 
(rare event, but time-sensitive, potentially high-risk situation) 
• Referral Personnel (Clinical Psychology - Dr. Rosman; Clinical Social Work – Lindsay 
Mosteller) very supportive of project.  
Recommendations:  
• Continue current screening process with NPs, Sarah Waters and Emily Baker.   
• Identify champion(s) to plan and initiate next steps:  
o Potentially a lead champion, provider champion, and/or nursing champion 
o Roll out process changes suggested by staff (e.g., best time to administer the screening; 
changes in who would document initial screening score; and which providers to roll out 
in the next phase). 
• Identify a champion to provide feedback on number of positive screens and received 
intervention(s). Consider implementing a regular audit to ensure that follow-up is documented for 
those who screen positive. 
• Add a case study approach to training nursing staff and providers such as: 1) case with elevated 




positive & deemed by provider to be depressed; 3) case with positive screening who expresses 
suicidal ideations 






APPENDIX I: COVID-19 TIMELINE 
3/6/2020  
UNC Spring break.  
 
3/10/2020  
State of Emergency by Governor Roy Cooper.  
 
3/11/2020  
Spring break extended by one week and in-person classes suspended starting 3/20/20.  
 
3/15/20  
Cardiology clinic shut down. 
 
3/19/20  
In-person clinicals suspended. 
 
3/23/20 through first week of 6/2020 
80% of HF encounters were telehealth visits. 
 
3/26/20  
Stay at home orders for Wake/Orange/Durham counties. 
 
3/30/20-5/8/20  
North Carolina statewide stay at home orders. 
 
4/6/2020  
Proposal approved by committee. 
 
3/23/20  
Telehealth visits started. 
 
4/29/20  
Project received IRB approval. 
 
5/28/20  
Lunch and learn via zoom (staff in person). NP participants selected 6/8/2020 as go-live. 
 
6/8/2020  
95% HF encounters were in-person clinic visits. 
 
6/24/20  
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